Kaye 3SP — Jan Delcoval

Access DB# 130535

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabrina Cruz Examiner #: 74141 Date: 6/23/04

Art Unit: 1616 Phone Number 30 20622 Serial Number: 10/627,526

Mail Box and Bldg/Room Location: 4C70, Rem, 4445 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Heterocyclic Compd

Inventors (please provide full names): Lohray et al

Earliest Priority Filing Date: Reissue of US 6,310,069

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Reissue of US Pat. 6,310,069.

New cl 25 added, drawn to specific compds covered by formula (III) ??

Please search for compds of formula (III) in cl. 1.

****

STAFF USE ONLY

Searcher: AR

Searcher Phone #: 22504

Searcher Location:

Date Searcher Picked Up: 8/24

Date Completed: 8/24

Searcher Prep & Review Time:

Clerical Prep Time: 45

Online Time: F 140

Type of Search

NA Sequence (#)

AA Sequence (#)

Structure (#) V

Bibliographic

Litigation

Fulltext

Patent Family

Other

Vendors and cost where applicable

STN V

Dialog

Questel/Orbit

Dr.Link

Lexis/Nexis

Sequence Systems

WWW/Internet

Other (specify)

PTO-1590 (8-01)

blood samples were collected one hour after administration of test compounds/vehicle for assessing the biological activity.

Test compounds were suspended on 0.25% carboxymethyl cellulose and administered to test group at a dose of 10 mg to 100 mg/kg through oral gavage daily for 6 days. The control group received vehicle (dose 10 ml/kg). Troglitazone (100 mg/kg, daily dose) was used as a standard drug which showed 28% reduction in random blood sugar level on 6th day.

The blood sugar and triglycerides lowering activities of the test compound was calculated according to the formula:

$$\text{Blood sugar/triglycerides lowering activity (\%)} = 1 - \frac{DT/DC}{TC/ZC} \times 100$$

ZC=Zero day control group value

DC=Zero day treated group value

TC=Control group value on test day

DT=Treated group value on the test day

No adverse effects were observed for any of the mentioned compounds of invention in the above test.

The compounds of the present invention also showed cholesterol lowering activity in the experimental animals used.

Compound	Dose mg/kg/da	Days treated	Maximum reduction in blood glucose level (%)	Triglyceride lowering (%)
Example 3	100	6	67	12
Example 6	100	6	41	31
Example 7	100	6	66	35
Example 9	30	6	46	35
Example 12	100	6	71	57
Example 13	100	6	52	57
Example 17	30	6	65	45
Example 19	30	6	73	70
Example 21	30	6	64	76
Example 22	30	6	55	41
Example 24	10	6	63	17
Example 11	30	6	32	42
Example 28	10	6	63	57

The experimental results from the db/db mice suggest that the novel compounds of the present invention also possess therapeutic utility as a prophylactic or regular treatment for obesity, cardiovascular disorders such as hypertension, hyperlipidaemia and other diseases; as it is known from the literature that such diseases are interrelated to each other.

What is claimed is:

1. An intermediate of formula (III)

(III)



where G represents —CHO, —NH_2, —CH=NOH, —CH_2NHOH, —CH_2N(OH)$CONH_2$ or —CH_2CH(J)-COOR, wherein J represents hydroxy or halogen atom and R represents hydrogen, or lower alkyl group; and of X, Y and Z represents C=O or C=S and one of the remaining of X, Y and Z represents a group C= and the other of the remaining of X, Y or Z represents C=C; with a proviso that when cyclic structure represented by X, Y and N form a pyrimidinone group, G does not represent CHO, R^1, R^2 and R^3 are the substituents either on X, Y or Z or on a nitrogen atom and are the same or different and represent hydrogen atom, halogen, hydroxy or nitro, or optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl selected from acetyl, propionyl or benzoyl; acyloxy selected from acetyloxy, propionyloxy, or benzoyloxy; hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, aryloxy, alkoxycarbonyl, alkylamino, alkoxyalkyl, thioalkyl, alkylthio or carboxylic acid or its amides or sulfonic acid or its amides with the provision that when R^1, R^2 or R^3 is on a nitrogen atom it does not represent hydrogen, halogen, hydroxy, nitro; or substituted or unsubstituted aryloxy, alkoxy, cycloalkoxy, acyloxy selected from acetyloxy, propionyloxy, or benzoyloxy; alkylthio, carboxy or sulfonic acid groups; or any two of R^1, R^2 and R^3 along with the adjacent atoms to which they are attached may form a substituted or unsubstituted cyclic structure of 4 to 7 atoms, with one or more double bonds, which are carbocyclic or optionally contain one or more heteroatoms selected from oxygen, nitrogen and sulfur; the linking group represented by —$(CH_2)_n$—O— is attached either through nitrogen atom or through X, Y or Z, where n is an integer ranging from 1–4; and Ar represents an optionally substituted divalent aromatic or heterocyclic group.

2. A pharmaceutical composition which comprises, a compound according to claim 1 as an effective ingredient and a pharmaceutically acceptable carrier, diluent or excipient.

* * * * *

```
=> d his

     (FILE 'HOME' ENTERED AT 14:07:04 ON 24 AUG 2004)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 14:07:14 ON 24 AUG 2004
L1             STR
L2           0 S L1 CSS SAM
L3             STR L1
L4             SCR 2039 OR 2127 OR 0250 OR 2049 OR 2048 OR 2053 OR 2052 OR 205
L5             SCR 1993 AND 1839
L6             SCR 1406 OR 382 OR 356
L7           0 S L3 AND L5 AND L6 NOT L4 CSS SAM

     FILE 'HCAPLUS' ENTERED AT 14:21:58 ON 24 AUG 2004
L8           4 S (US6310069 OR US6114526 OR US5985884 OR US5885997)/PN OR IN96
               E LOHRAY V/AU
L9          47 S E4-E10
               E LOHRAY B/AU
L10        121 S E4-E10
               E PARASELLI R/AU
L11         12 S E4
               E GURRAM R/AU
L12         11 S E4
               E RAMANUJAM R/AU
L13         48 S E3,E4
               E CHAKRABARTI R/AU
L14        154 S E3-E7,E15-E16
               E PAKALA S/AU
L15          3 S E5
               E REDDY/AP,CS
               E REDDY/PA,CS
L16        385 S E3-E61
               E DR REDDY/PA,CS
L17         55 S E5-E37
L18          4 S L8 AND L9-L17
               SEL RN

     FILE 'REGISTRY' ENTERED AT 14:27:49 ON 24 AUG 2004
L19        123 S E1-E123
L20         47 S L19 AND NCNC3-C6/ES
L21         41 S L20 AND 46.150.18/RID
L22         13 S L21 AND 3/NR
L23         11 S L22 NOT NITRO
L24         76 S L19 NOT L20
L25         51 S L24 AND NCNC3/ES
L26         44 S L25 AND 46.150.18/RID
L27         17 S L26 AND 2/NR
L28         16 S L27 NOT NITRO
L29          9 S L28 NOT ALDEHYDE
L30          3 S L29 AND (C12H12N2O OR C15H15N3O4)
L31          1 S L29 AND C16H21N3O3
L32          5 S L29 NOT L30,L31
L33         56 S L19 AND S/ELS
L34         53 S L33 AND 46.150.18/RID
L35          2 S L34 AND SC4-NCNC3/ES
L36          1 S L35 AND 3/NR
L37         12 S L19 AND NCNC3/ES AND 46.150.18/RID AND 2/NR NOT L32
L38          2 S L37 AND (C16H21N3O3 OR C16H19N3O3)
L39        100 S L19 AND 46.150.18/RID
L40         57 S L39 AND ETHOXY
L41         15 S L40 AND ALDEHYDE
L42          1 S C17H15N3O3 AND L41
```

```
L43          42 S L40 NOT L41
L44          14 S L43 NOT NCSC2/ES
L45          19 S L23,L32,L36,L38
L46          81 S L39 NOT L45
L47          29 S L46 NOT S/ELS
L48          24 S L47 NOT NITRO
L49          23 S L48 NOT ACETAMIDE
L50          19 S L49 NOT NCOC2/ES
L51          15 S L50 AND NR>=2
L52          11 S L51 NOT NOCNC/ES
L53          20 S L45,L42

     FILE 'HCAOLD' ENTERED AT 15:01:23 ON 24 AUG 2004
L54           0 S L53

     FILE 'HCAPLUS' ENTERED AT 15:01:26 ON 24 AUG 2004
L55           5 S L53
L56           5 S L55 AND L8-L18

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:02:09 ON 24 AUG 2004
L57           9 S L53

     FILE 'REGISTRY' ENTERED AT 15:05:28 ON 24 AUG 2004

     FILE 'HCAPLUS' ENTERED AT 15:06:55 ON 24 AUG 2004

     FILE 'USPATFULL, USPAT2' ENTERED AT 15:07:43 ON 24 AUG 2004

     FILE 'REGISTRY' ENTERED AT 15:36:06 ON 24 AUG 2004
L58             STR L3
L59           1 S L58 AND L5 AND L6 NOT L4 SAM

     FILE 'HCAPLUS' ENTERED AT 15:43:05 ON 24 AUG 2004
                E DIABETES/CT
L60       12433 S E4+OLD,NT,PFT,RT
L61       79998 S E12+OLD,NT,PFT,RT
L62       10753 S E3
                E E3+ALL
                E E2+ALL
L63       10753 S E3
                E E3+ALL
                E E3+ALL
                E E19+ALL
L64        9093 S E5,E6,E4
                E E10+ALL
                E E17+ALL
L65       15493 S E4,E5,E3,E13

     FILE 'REGISTRY' ENTERED AT 15:44:53 ON 24 AUG 2004
L66           3 S INSULIN/CN OR GLUCOSE/CN

     FILE 'HCAPLUS' ENTERED AT 15:44:59 ON 24 AUG 2004
L67      238719 S L66
L68      167931 S ?INSULIN?
L69       86208 S L60-L65
L70      386550 S GLUCOSE OR BLOOD SUGAR
L71       55633 S L67,L68,L70 AND L69
L72       86208 S L69,L71
L73       47745 S L72 AND (PY<=1996 OR PRY<=1996 OR AY<=1996)
L74        1698 S L73 AND HET?/SC,SX
L75        4703 S L73 AND P/DT
L76        5044 S L74,L75
L77        5044 S L76 OR L76
```

```
L78          500 S L77  RAN=(1998:239219,)
L79          500 S L77  RAN=(1997:356528,1998:239217)
L80          500 S L77  RAN=(1996:211894,1997:354052)
L81          500 S L77  RAN=(1994:631055,1996:211760)
L82          500 S L77  RAN=(1992:563880,1994:628810)
L83          500 S L77  RAN=(1990:151885,1992:557663)
L84          500 S L77  RAN=(1986:553495,1990:151877)
L85          500 S L77  RAN=(1981:587068,1986:553059)
L86         1044 S L77 NOT L78-L85

      FILE 'REGISTRY' ENTERED AT 15:52:11 ON 24 AUG 2004

      FILE 'HCAPLUS' ENTERED AT 15:52:11 ON 24 AUG 2004
                SET SMARTSELECT ON
L87           SEL L86 1- RN :   20641 TERMS
                SET SMARTSELECT OFF

      FILE 'REGISTRY' ENTERED AT 15:52:46 ON 24 AUG 2004
L88         20640 S L87

      FILE 'HCAPLUS' ENTERED AT 15:53:56 ON 24 AUG 2004
                SET SMARTSELECT ON
L89           SEL L85 1- RN :   15095 TERMS
                SET SMARTSELECT OFF

      FILE 'REGISTRY' ENTERED AT 15:54:15 ON 24 AUG 2004
L90         15094 S L89

      FILE 'HCAPLUS' ENTERED AT 15:55:03 ON 24 AUG 2004
                SET SMARTSELECT ON
L91           SEL L84 1- RN :   13449 TERMS
                SET SMARTSELECT OFF

      FILE 'REGISTRY' ENTERED AT 15:55:20 ON 24 AUG 2004
L92         13448 S L91

      FILE 'HCAPLUS' ENTERED AT 15:56:01 ON 24 AUG 2004
                SET SMARTSELECT ON
L93           SEL L83 1- RN :   16048 TERMS
                SET SMARTSELECT OFF

      FILE 'REGISTRY' ENTERED AT 15:56:18 ON 24 AUG 2004
L94         16048 S L93

      FILE 'HCAPLUS' ENTERED AT 15:57:05 ON 24 AUG 2004
                SET SMARTSELECT ON
L95           SEL L82 1- RN :   10369 TERMS
                SET SMARTSELECT OFF

      FILE 'REGISTRY' ENTERED AT 15:57:21 ON 24 AUG 2004
L96         10369 S L95

      FILE 'HCAPLUS' ENTERED AT 15:57:54 ON 24 AUG 2004
                SET SMARTSELECT ON
L97           SEL L81 1- RN :   17667 TERMS
                SET SMARTSELECT OFF

      FILE 'REGISTRY' ENTERED AT 15:58:15 ON 24 AUG 2004
L98         17667 S L97

      FILE 'HCAPLUS' ENTERED AT 15:59:15 ON 24 AUG 2004
                SET SMARTSELECT ON
L99           SEL L80 1- RN :   15411 TERMS
```

```
                SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 15:59:36 ON 24 AUG 2004
L100      15411 S L99

     FILE 'HCAPLUS' ENTERED AT 16:00:21 ON 24 AUG 2004
                SET SMARTSELECT ON
L101         SEL L79 1- RN :   23067 TERMS
                SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 16:00:47 ON 24 AUG 2004
L102      23067 S L101

     FILE 'HCAPLUS' ENTERED AT 16:01:51 ON 24 AUG 2004
                SET SMARTSELECT ON
L103         SEL L78 1- RN :   30314 TERMS
                SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 16:02:21 ON 24 AUG 2004
L104      30314 S L103

     FILE 'HCAPLUS' ENTERED AT 16:03:45 ON 24 AUG 2004
L105        546 S L8-L18,L56 NOT L76

     FILE 'REGISTRY' ENTERED AT 16:04:14 ON 24 AUG 2004

     FILE 'HCAPLUS' ENTERED AT 16:04:17 ON 24 AUG 2004
                SET SMARTSELECT ON
L106         SEL L105 1- RN :   13464 TERMS
                SET SMARTSELECT OFF

    FILE 'REGISTRY' ENTERED AT 16:04:43 ON 24 AUG 2004
L107      13464 S L106
L108     151807 S L88,L90,L92,L94,L96,L98,L100,L102,L104,L107
L109          1 S L1 CSS SAM SUB=L108
L110        155 S L1 CSS FUL SUB=L108
                SAV L110 QAZI697/A
                SAV L19 QAZI697A/A
L111        126 S L110 NOT L19
L112          1 S L111 AND NCNC3/ES
L113          5 S L111 AND NCNC3-C6/ES
L114          0 S L111 AND NCNC3-NC5/ES
L115          2 S L58 SAM SUB=L110
L116        101 S L58 FUL SUB=L110
                SAV L116 QAZI697B/A
L117         66 S L116 NOT L19,L112,L113
L118         41 S L117 NOT PIPERAZIN?
L119         34 S L118 NOT PYRAZOL?
L120          9 S L119 NOT IMIDAZOL?
L121          2 S L118 AND NCNC2-NC5/ES
L122          8 S L112,L113,L121
L123         64 S L117 NOT L122

    FILE 'HCAPLUS' ENTERED AT 16:18:47 ON 24 AUG 2004
L124          6 S L122
L125          4 S L124 AND (PY<=1996 OR PRY<=1996 OR AY<=1996)
L126          2 S L124,L125 AND L8-L18
L127          4 S L124,L125 NOT L126

=> fil reg
FILE 'REGISTRY' ENTERED AT 16:20:06 ON 24 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2004 HIGHEST RN 731771-88-3
DICTIONARY FILE UPDATES: 23 AUG 2004 HIGHEST RN 731771-88-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d l1
L1 HAS NO ANSWERS
L1 STR



REP G1=(1-4) CH2
VAR G2=CHO/N/17/20/26/6
VAR G3=X/OH
VAR G4=OH/16
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 1
CONNECT IS M1 RC AT 4
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M2 N AT 1

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

=> d ide can tot l122

L122 ANSWER 1 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
RN 471907-41-2 REGISTRY

CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-phenyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H21 N3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:310927

L122 ANSWER 2 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
RN 220746-27-0 REGISTRY
CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-hydroxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H18 N2 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:196665

L122 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
RN 220746-26-9 REGISTRY
CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C21 H22 N2 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 130:196665

L122 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
RN 194713-71-8 REGISTRY
CN Benzaldehyde, 4-[2-[1,4-dihydro-4-oxo-1-(2-pyridinyl)-3(2H)-quinazolinyl]ethoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H19 N3 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:205585

L122 ANSWER 5 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN

RN 194713-70-7 REGISTRY
CN Benzaldehyde, 4-[2-(1,4-dihydro-1-methyl-4-oxo-3(2H)-quinazolinyl)ethoxy]-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:205585

L122 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
RN 194713-69-4 REGISTRY
CN Benzaldehyde, 4-[2-(1,4-dihydro-4-oxo-1-phenyl-3(2H)-quinazolinyl)ethoxy]-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H20 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:205585

L122 ANSWER 7 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
RN 193544-83-1 REGISTRY
CN Benzaldehyde, 4-[(3-methyl-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]-
(9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C21 H17 N3 O2
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:161819

L122 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2004 ACS on STN
RN 172648-52-1 REGISTRY
CN Benzaldehyde, 4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H13 N3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:270847

REFERENCE 2: 124:87002

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:20:28 ON 24 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2004 VOL 141 ISS 9
FILE LAST UPDATED: 23 Aug 2004 (20040823/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot l126

L126 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:793609 HCAPLUS
DN 137:310927
ED Entered STN: 18 Oct 2002
TI Preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents
IN Iqbal, Javed; **Gurram, Ranga Madhavan**; Das, Saibal Kumar; Bhuniya, Debnath; **Chakrabarti, Ranjan**; **Ramanujam, Rajagopalan**
PA **Reddy's Laboratories Ltd., India**
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D239-36
ICS A61K031-513; A61P003-10
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002081454	A1	20021017	WO 2002-IB1104	20020408
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003013729	A1	20030116	US 2002-119300	20020408
PRAI	IN 2001-MA301	A	20010409		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002081454	ICM	C07D239-36
	ICS	A61K031-513; A61P003-10

OS MARPAT 137:310927
GI



I



II

AB Title compds. I [X = O, S; R1-3= H, halo, OH, NO2, CN, CHO, etc.; R3 when attached to nitrogen atom = H, OH, CHO, etc.; W = O, S, amino, C(O), OCO, etc.; m, n = 0-4; Ar= divalent single or fused aromatic or heterocyclic group; R4-5 = H, OH, alkoxy, halo, etc.; R6 = H, alkyl, cycloalkyl, etc.; Y = O, NR8; R8 = H, alkyl, aryl, etc.; R6,R8 together may form a (un)substituted 5-6-membered (hetero)cycle; Q= O, S, SO, SO2, etc.; p = 0-1] were prepared For instance, 2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)acetic acid and Et 3-methyl-2-(4-heptylaminophenylthio)butanoa te (preparation of starting materials given) were coupled (CH2Cl2, DIC, HOBt) to afford II. Selected example compds. at 3 mg/kg (mice) orally reduced triglycerides in mice by 36-44%. I are useful for the treatment of, e.g., obesity.

ST pyrimidine amide aryl acid prepn ppar cholesterol tricglyceride obesity; hypolipidemic aryloxyacetic acid prepn

IT Antiarteriosclerotics
(antiatherosclerotics; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Drug delivery systems
(capsules; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Heart, disease
(cardiac syndrome X; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Artery, disease
(coronary; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Mental disorder
(dementia; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Appetite
(disorder; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dyslipidemia; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Intestine, disease
(inflammatory; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(low-d.; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Muscular dystrophy
(myotonic; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Kidney, disease
(nephrosclerosis, hypertensive; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Pancreas, disease
(pancreatitis; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Ovary, disease
(polycystic; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Drug delivery systems
(powders; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Antiarteriosclerotics
Anticholesteremic agents
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antitumor agents
Arteriosclerosis
Atherosclerosis
Cardiovascular system, disease
Diabetes insipidus
Diabetes mellitus
Human
Hyperglycemia
Hypertension
Hypolipemic agents
Kidney, disease
Neoplasm
Obesity
Osteoporosis
Psoriasis
(pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Fatty acids, biological studies
Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Eye, disease
(retinopathy; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Drug delivery systems
(solns.; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Brain, disease
(stroke; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Drug delivery systems
(suspensions; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Drug delivery systems
(syrups; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)
IT Drug delivery systems
(tablets; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Osteoporosis
(therapeutic agents; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(very-low-d.; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Skin, disease
(xanthoma; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT 59-67-6, Nicotinic acid, biological studies 11041-12-6, Cholestyramine 23288-49-5, Probucol 50925-79-6, Cholestipol 96829-58-2, Orlistat 163222-33-1, Ezetimibe
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT 23501-39-5P, Ethyl 2-methyl-2-(4-nitrophenyloxy)propanoate 42806-90-6P 471907-17-2P 471907-18-3P 471907-19-4P 471907-20-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)

IT 471906-95-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)

IT 471906-03-3P 471906-04-4P 471906-05-5P 471906-06-6P 471906-07-7P
471906-08-8P 471906-09-9P 471906-10-2P 471906-11-3P 471906-12-4P
471906-13-5P 471906-14-6P 471906-15-7P 471906-16-8P 471906-17-9P
471906-18-0P 471906-19-1P 471906-20-4P 471906-21-5P 471906-22-6P
471906-23-7P 471906-24-8P 471906-25-9P 471906-26-0P 471906-27-1P
471906-28-2P 471906-29-3P 471906-30-6P 471906-31-7P 471906-32-8P
471906-33-9P 471906-34-0P 471906-35-1P 471906-36-2P 471906-37-3P
471906-38-4P 471906-39-5P 471906-40-8P 471906-42-0P 471906-43-1P
471906-44-2P 471906-45-3P 471906-46-4P 471906-47-5P 471906-48-6P
471906-49-7P 471906-50-0P 471906-51-1P 471906-52-2P 471906-53-3P
471906-54-4P 471906-55-5P 471906-56-6P 471906-57-7P 471906-58-8P
471906-59-9P 471906-60-2P 471906-61-3P 471906-62-4P 471906-63-5P
471906-64-6P 471906-65-7P 471906-66-8P 471906-67-9P 471906-68-0P
471906-69-1P 471906-70-4P 471906-71-5P 471906-72-6P 471906-73-7P
471906-74-8P 471906-75-9P 471906-76-0P 471906-77-1P 471906-78-2P
471906-79-3P 471906-80-6P 471906-81-7P 471906-82-8P 471906-83-9P
471906-84-0P 471906-85-1P 471906-86-2P 471906-87-3P 471906-88-4P
471906-89-5P 471906-90-8P 471906-91-9P 471906-92-0P 471906-93-1P
471906-94-2P 471906-96-4P 471906-97-5P 471906-98-6P 471906-99-7P
471907-00-3P 471907-01-4P 471907-02-5P 471907-04-7P 471907-05-8P
471907-06-9P 471907-07-0P 471907-08-1P 471907-09-2P 471907-10-5P
471907-11-6P 471907-12-7P 471907-13-8P 471907-14-9P 471907-15-0P
471907-16-1P 471907-43-4P 471907-44-5P 471907-45-6P 471907-46-7P
471907-47-8P 472961-40-3P 472961-56-1P 472961-58-3P 472961-60-7P
472961-62-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)

IT 74-79-3, L-Arginine, reactions 105-36-2, Ethyl bromoacetate 123-30-8, p-Aminophenol 535-11-5, Ethyl 2-bromopropanoate 629-04-9, Heptyl bromide 637-89-8, 4-Hydroxythiophenol 5445-29-4, Ethyl 2-bromooctanoate 52421-76-8 53844-02-3, 2-Benzyloxycarbonylaminoethyl bromide 471907-40-1, 1-(2-Chloroethyl)-2-ethyl-4-phenyl-1,6-dihydropyrimidin-6-one **471907-41-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)

IT 28048-87-5P, Ethyl 2-methyl-2-(4-aminophenyloxy)propanoate 287393-36-6P 471907-21-8P 471907-22-9P 471907-23-0P, Ethyl 2-(4-aminophenyloxy)octanoate 471907-24-1P 471907-25-2P 471907-26-3P 471907-27-4P 471907-28-5P 471907-29-6P, Ethyl 3-methyl-2-[[4-heptylaminophenyl]sulfanyl]butanoate 471907-30-9P 471907-31-0P 471907-32-1P 471907-33-2P 471907-34-3P 471907-35-4P, 2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)acetic acid 471907-36-5P, Ethyl 2-(2-ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)acetate 471907-37-6P, 2-(2-Ethyl-6-oxo-4-phenyl-1,6-dihydro-1-pyrimidinyl)ethylamine 471907-38-7P 471907-39-8P, 2-Ethyl-1-[2-(4-hydroxyphenylsulfanyl)ethyl]-4-phenyl-1,6-dihydropyrimidin-6-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)

IT 57-88-5, Cholesterol, biological studies 9028-35-7, HMG CoA reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

IT 100-02-7, 4-Nitrophenol, reactions 600-00-0, Ethyl 2-bromoisobutyrate
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as hypolipidemic agents)

IT 9004-10-8, Insulin, biological studies 169494-85-3, Leptin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; pyrimidinyl-amido-aryl(thio)oxy carboxylic acid PPARα/γ ligands used as hypolipidemic agents)

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Artico, R; BIOCHEM PHARMACOL 1968, V17(6), P893
(2) Borck, J; US 3804839 A 1974 HCAPLUS
(3) Bordi, F; FARMACO 1989, V44(9), P795 HCAPLUS
(4) Condon, M; US 5523277 A 1996 HCAPLUS
(5) Fuji Photo Film Co Ltd; DE 3634862 A 1987 HCAPLUS
(6) Green Cross Corp; EP 0712844 A 1996 HCAPLUS
(7) Hoechst Celanese Corp; EP 0334598 A 1989 HCAPLUS
(8) Ici Plc; EP 0248554 A 1987 HCAPLUS
(9) Kuliev, A; AZERB KHIM ZH, CAPLUS Acc No 1970:12299 1969, V2, P74 HCAPLUS
(10) Liu, C; HUAXUE YANJIU YU YINGYONG, CAPLUS Acc No 1997:766522 1997, V9(5), P497 HCAPLUS
(11) Marcos, M; CHEM MATER, CAPLUS Acc No 1993:614333 1993, V5(9), P1332 HCAPLUS
(12) Nissan Chemical Ind Ltd; EP 0636615 A 1995 HCAPLUS
(13) Reddy Research Foundation; WO 9908501 A 1999 HCAPLUS
(14) Sankyo Co; EP 0587311 A 1994 HCAPLUS
(15) Schacht, E; US 3992386 A 1976 HCAPLUS
(16) Torii, Y; JP 20-00159751 A 2000 HCAPLUS

IT **471907-41-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidinyl-amido-aryl(thio)oxy carboxylic acids as

hypolipidemic agents)
RN 471907-41-2 HCAPLUS
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-phenyl- (9CI) (CA INDEX NAME)



L126 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:152363 HCAPLUS
DN 130:196665
ED Entered STN: 09 Mar 1999
TI Preparation of ω-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPARα and PPARγ receptor agonists
IN **Lohray, Vidya Hushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Ramanujam, Rajagopalan; Chakrabarti, Ranjan**
PA **Reddy's Research Foundation, India; Reddy-Cheminor, Inc.**
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
IC C07D000-00
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9908501	A2	19990225	WO 1998-US22568	19981026
	WO 9908501	A3	19990415		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9911205	A1	19990308	AU 1999-11205	19981026
	EP 1073643	A2	20010207	EP 1998-953969	19981026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-82825P	P	19980423		
	WO 1998-US22568	W	19981026		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9908501	IC	C07D000-00

OS MARPAT 130:196665
GI



I

AB Title compds. [I; R = (CH2)nOZCHR4CR5(OR6)COYR7 and R3 = H, halo, alkyl, alkoxy, etc.; R = H, OH, acyl, alkyl, etc.; and R3 = (CH2)nOZCHR4CR5(OR6)COYR7; R1,R2 = H, halo, alkyl, alkoxy, etc.; R1R2 = atoms to complete a ring; R4,R5 = H, halo, alkyl, alkoxy, etc.;; R4R5 = bond; R6 = H, acyl, alkyl aryl, etc.; R7 = H, alkyl, heterocyclyl, (hetero)aryl, etc.; X = O or S; Y = O or NR8; R8 = H, alkyl, aryl, etc.; R7R8 = atoms to complete a ring; Z = (hetero)arylene; n = 1-4] were prepared Thus, I (R = Me, R1R2 = CH:CHCH:CH, X = O)(II; R3 = CH2Cl) was condensed with 4-(HO)C6H4CH2CH(OEt)CO2Et to give II [R3 = CH2OC6H4[CH2CH(OEt)CO2Et]-4]. Data for biol. activity of I were given.

ST oxoquinazolinylalkoxyphenylalkanoate prepn PPAR alpha gamma receptor agonist; antiobesity oxoquinazolinylalkoxyphenylalkanoate prepn; hypocholesteremic oxoquinazolinylalkoxyphenylalkanoate prepn

IT Anticholesteremic agents
Antiobesity agents
(preparation of ω-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPARα and PPARγ receptor agonists)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(α, regulated functions; enhancement; preparation of ω-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPARα and PPARγ receptor agonists)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)
(γ, regulated functions; enhancement; preparation of ω-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPARα and PPARγ receptor agonists)

IT 220746-16-7P 220746-17-8P 220746-18-9P 220746-19-0P 220746-20-3P
220746-21-4P 220746-22-5P 220746-23-6P 220746-24-7P 220746-25-8P
220746-26-9P 220746-27-0P 220746-28-1P 220746-29-2P
220746-30-5P 220746-31-6P 220746-32-7P 220746-33-8P 220746-34-9P
220746-35-0P 220746-36-1P 220746-37-2P 220746-39-4P 220746-42-9P
220746-43-0P 220746-45-2P 220746-47-4P 220746-48-5P 220746-49-6P
220746-50-9P 220746-51-0P 220746-52-1P 220746-53-2P 220746-54-3P
220746-56-5P 220746-57-6P 220746-58-7P 220746-59-8P 220746-60-1P
220746-61-2P 220746-62-3P 220746-63-4P 220746-64-5P 220746-65-6P
220746-66-7P 220746-67-8P 220746-68-9P 220746-70-3P 220746-71-4P
220746-72-5P 220746-73-6P 220746-74-7P 220746-75-8P 220746-76-9P
220746-77-0P 220746-78-1P 220746-79-2P 220746-80-5P 220746-81-6P
220746-82-7P 220746-83-8P 220746-85-0P 220746-86-1P 220746-87-2P
220746-88-3P 220746-89-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ω-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPARα and PPARγ receptor agonists)

IT 79-03-8, Propanoyl chloride 100-39-0, Benzyl bromide 106-94-5, Propyl bromide 109-65-9, Butyl bromide 110-91-8, Morpholine, reactions 111-83-1, Octyl bromide 118-48-9, Isatoic anhydride 348-54-9, 2-Fluoroaniline 491-36-1, 4-Quinazolinone 1769-24-0 3137-64-2 4397-53-9, 4-Benzyloxybenzaldehyde 13676-06-7, Ethyl

(diethylphosphono)ethoxyacetate 16858-50-7 20989-17-7, (S)-2-Phenylglycinol 22312-77-2 22312-80-7 22312-82-9 39263-96-2 62517-34-4 149806-75-7, 4-(2-Azidoethoxy)benzaldehyde 197299-16-4 199114-62-0 220746-97-4 220746-98-5 220747-00-2 220747-01-3 220747-02-4 220747-04-6 220747-05-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of ω-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPARα and PPARγ receptor agonists)

IT 197299-09-5P 220746-90-7P 220746-91-8P 220746-92-9P 220746-93-0P 220746-94-1P 220746-95-2P 220746-96-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ω-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPARα and PPARγ receptor agonists)

IT **220746-26-9P 220746-27-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ω-[(oxoquinazolinylalkoxy)phenyl]alkanoates and analogs as PPARα and PPARγ receptor agonists)

RN 220746-26-9 HCAPLUS
CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 220746-27-0 HCAPLUS
CN Benzenepropanoic acid, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



=> d all hitstr tot l127

L127 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:264243 HCAPLUS
DN 140:270847
ED Entered STN: 01 Apr 2004
TI Preparation of antidiabetic 5-(heterocyclylmethoxybenzyl)thiazolidine-2,4-

diones and their intermediates
IN Fujita, Takashi; Yoshioka, Takao; Fujiwara, Toshihiko; Oguchi, Minoru; Yanagisawa, Hiroaki; Horikoshi, Hiroyoshi; Wada, Kunio; Fujimoto, Koichi
PA Sankyo Company, Limited, Japan
SO U.S., 87 pp., Division of U.S. 5,624,935.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D277-04
ICS C07D263-04
NCL 548183000; 548226000
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5739345	A	19980414	US 1996-745377	19961108 <--
	HU 72627	A2	19960528	HU 1995-2600	19950411 <--
	US 5624935	A	19970429	US 1995-419919	19950411 <--
	IL 115269	A1	19990620	IL 1995-115269	19950912 <--
	US 5834501	A	19981110	US 1996-713543	19960913 <--
	US 5962470	A	19991005	US 1997-1093	19971230 <--
	US 5977365	A	19991102	US 1998-110693	19980707 <--
	AU 9887093	A1	19981203	AU 1998-87093	19980928 <--
	AU 712294	B2	19991104		
	US 6117893	A	20000912	US 1999-261645	19990303 <--
PRAI	JP 1994-72083	A	19940411 <--		
	US 1995-419919	A3	19950411 <--		
	IL 1995-113313	A3	19950410 <--		
	HU 1995-1040	A	19950411 <--		
	US 1996-713543	A3	19960913 <--		
	AU 1997-32443	A3	19970801		
	US 1997-1093	A3	19971230		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5739345	ICM	C07D277-04
	ICS	C07D263-04
	NCL	548183000; 548226000

OS MARPAT 140:270847
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = (un)substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl, or imidazopyrimidinyl; Y = O or S; Z = 2,4-dioxo-thiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydroxyureidomethyl; R = H, (ar)alkyl, alkoxy, halo, OH, NO2, or (un)substituted amino; m = 1-5; and salts thereof] were prepared as hypoglycemic and antidiabetic agents. Also disclosed are intermediate compds. II [wherein Q = alkoxycarbonyl, CHO, CO2H, or OH; Y = O or S; Y' = S; R = H, (ar)alkyl, alkoxy, halo, OH, NO2, or (un)substituted amino; m = 1-5; and salts thereof] for the preparation of I. For example, 5-chloro-2-hydroxymethyl-3-methylimidazo[5,4-b]pyridine was condensed with 5-(4-hydroxybenzyl)-3-triphenylmethylthiazolidine-2,4-dione in the presence of PBu3 and 1,1'-(azodicarbonyl)dipiperidine in THF to give 5-[4-(5-chloro-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl]-3-triphenylmethylthiazolidine-2,4-dione. Deprotection using AcOH and H2O provided III, which lowered blood glucose levels in hyperglycemic male KK

mice by 37.1% at a dose of 1 mg/kg and inhibited aldose reductase activity with IC50 of 1.8 μM/mL. In toxicity expts., oral administration of 50 mg/kg III to ohm male F344 rats for 2 wk produced no abnormalities and resulted in a zero mortality rate.

ST heterocyclylmethoxybenzyl thiazolidinedione prepn hypoglycemic antidiabetic

IT Antidiabetic agents
Diabetes mellitus
Hyperglycemia
(preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

IT 50-99-7, D-Glucose, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(blood; preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

IT 172647-54-0P 172647-64-2P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

IT 9028-31-3, Aldose reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

IT 172647-48-2P 172647-49-3P 172647-50-6P 172647-51-7P 172647-52-8P
172647-53-9P 172647-55-1P 172647-56-2P 172647-57-3P 172647-58-4P
172647-59-5P 172647-60-8P 172647-61-9P 172647-62-0P 172647-63-1P
172647-65-3P 172647-66-4P 172647-67-5P 172647-68-6P 172647-69-7P
172647-70-0P 172647-71-1P 172647-72-2P 172647-73-3P 172647-74-4P
172647-75-5P 172647-76-6P 172647-77-7P 172647-78-8P 172647-79-9P
172647-80-2P 172647-81-3P 172647-82-4P 172647-83-5P 172647-84-6P
172647-85-7P 172647-86-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

IT 54-96-6, 4,5-Diaminopyridine 96-32-2, Methyl bromoacetate 96-48-0, γ-Butyrolactone 100-02-7, reactions 100-51-6, Benzenemethanol, reactions 104-86-9, 4-Chlorobenzylamine 108-98-5, Thiophenol, reactions 120-72-9, Indole, reactions 123-08-0, 4-Hydroxybenzaldehyde 141-32-2 271-63-6, 7-Azaindole 452-58-4, 2,3-Diaminopyridine 504-29-0, 2-Aminopyridine 623-50-7, Ethyl glycolate 637-81-0, Ethyl azidoacetate 638-07-3, Ethyl 4-chloroacetoacetate 1072-97-5, 2-Amino-5-bromopyridine 1072-98-6, 2-Amino-5-chloropyridine 1667-11-4, 4-(Chloromethyl)biphenyl 2032-35-1, Bromoacetaldehyde diethyl acetal 5470-18-8, 2-Chloro-3-nitropyridine 6332-56-5, 2-Hydroxy-3-nitropyridine 6602-54-6, 2-Chloro-3-cyanopyridine 16013-85-7, 2,6-Dichloro-3-nitropyridine 24638-20-8, 1H-Imidazo[4,5-b]pyridine-2-methanol 27048-04-0 38922-77-9, Ethyl imidazo[1,2-a]pyridine-2-carboxylate 74772-78-4 78348-24-0, Indoline-2-carboxylic acid 92381-62-9, 1H-Imidazo[4,5-c]pyridine-2-methanol 115951-72-9 150556-72-2 172648-54-3 172648-55-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

IT 591-81-1P, 4-Hydroxybutyric acid 1485-22-9P 3723-71-5P 4093-88-3P, 2-Methylamino-3-nitropyridine 5028-20-6P 5409-39-2P 6642-26-8P, 1H-Purine-8-methanol 6945-68-2P, 2-Amino-5-bromo-3-nitropyridine 19786-48-2P 21755-34-0P 21755-54-4P, Imidazo[1,2-a]pyridine-2-ethanol 25710-20-7P, 5-Chloro-2,3-diaminopyridine 32282-18-1P 32329-12-7P 33140-80-6P 33742-70-0P 34949-41-2P 36404-88-3P,

2-Chloro-3-formylpyridine 37493-34-8P 38875-53-5P,
5-Bromo-2,3-diaminopyridine 39597-68-7P 40851-95-4P,
6-Chloro-2,3-diaminopyridine 41010-49-5P 42048-25-9P 50501-07-0P,
Ethyl indoline-2-carboxylate 59954-04-0P, Methyl 4-aminophenoxyacetate
76182-48-4P 82090-52-6P, Imidazo[1,2-a]pyridine-2-methanol 90817-34-8P
90874-78-5P 90929-77-4P, 1H-Pyrrolo[2,3-b]pyridine-1-ethanol
91371-83-4P 94166-58-2P 121459-15-2P, 1H-Indole-1-ethanol
138969-57-0P 148433-49-2P 164224-08-2P 172647-87-9P 172647-88-0P
172647-89-1P 172647-90-4P 172647-91-5P 172647-92-6P 172647-93-7P
172647-94-8P 172647-95-9P 172647-96-0P 172647-97-1P 172647-98-2P
172647-99-3P 172648-00-9P 172648-01-0P 172648-02-1P,
1H-Imidazo[4,5-b]pyridine-2-propanol 172648-03-2P 172648-04-3P
172648-05-4P 172648-06-5P 172648-07-6P 172648-08-7P 172648-09-8P
172648-10-1P 172648-11-2P 172648-12-3P 172648-13-4P 172648-14-5P
172648-15-6P 172648-16-7P 172648-17-8P 172648-18-9P 172648-19-0P
172648-20-3P 172648-21-4P 172648-22-5P 172648-23-6P 172648-24-7P
172648-25-8P 172648-26-9P 172648-27-0P 172648-28-1P 172648-29-2P
172648-30-5P 172648-31-6P 172648-32-7P 172648-33-8P 172648-34-9P
172648-35-0P 172648-36-1P 172648-37-2P 172648-38-3P 172648-39-4P
172648-40-7P 172648-41-8P 172648-42-9P 172648-43-0P 172648-44-1P
172648-45-2P 172648-46-3P 172648-47-4P 172648-48-5P 172648-49-6P
172648-50-9P 172648-51-0P **172648-52-1P** 172648-53-2P
172648-56-5P 172648-57-6P 172648-58-7P 172648-59-8P 172648-60-1P
172648-61-2P 172648-62-3P 172648-63-4P 298231-55-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; JP 53-1217758 1978
(2) Anon; EP 0008203 1980 HCAPLUS
(3) Anon; EP 0139421 1985 HCAPLUS
(4) Anon; EP 0177353 1986 HCAPLUS
(5) Anon; EP 0208420 1987 HCAPLUS
(6) Anon; EP 0306228 1989 HCAPLUS
(7) Anon; EP 0356214 1990 HCAPLUS
(8) Anon; EP 0441605 1991 HCAPLUS
(9) Anon; WO 9107107 1991 HCAPLUS
(10) Anon; WO 9202520 1992 HCAPLUS
(11) Anon; WO 9203425 1992 HCAPLUS
(12) Anon; WO 9207839 1992 HCAPLUS
(13) Anon; WO 9207850 1992 HCAPLUS
(14) Anon; EP 0528734 1993 HCAPLUS
(15) Austin, P; The Ring Index-2nd Edition 1960, P157
(16) Hindley; US 5075300 1991 HCAPLUS
(17) Takebayashi; US 5387596 1995 HCAPLUS
(18) Yoshioka; US 4572912 1986 HCAPLUS
(19) Yoshioka; US 4691027 1987 HCAPLUS
(20) Yoshioka; US 4871762 1989 HCAPLUS
(21) Yoshioka; US 4873255 1989 HCAPLUS
(22) Yoshioka; US 5104888 1992 HCAPLUS
(23) Yoshioka; US 5143930 1992 HCAPLUS
(24) Yoshioka; US 5338855 1994 HCAPLUS

IT **172648-52-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of antidiabetic (heterocyclylmethoxybenzyl)thiazolidinediones and their intermediates)

RN 172648-52-1 HCAPLUS
CN Benzaldehyde, 4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]- (9CI) (CA INDEX NAME)



L127 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:553183 HCAPLUS
DN 127:205585
ED Entered STN: 30 Aug 1997
TI Preparation of benzoazines for reducing blood glucose level
IN Nagao, Yoshihiro; Ito, Yoshikuni; Kotake, Jiro; Kouda, Tadayuki; Honda, Haruyoshi; Sato, Susumu; Matsuda, Hideaki
PA SS Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07D417-12
ICS A61K031-425; A61K031-505
CC 28-13 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 787727	A1	19970806	EP 1997-101626	19970131 <--
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	TW 399051	B	20000721	TW 1997-86100906	19970128 <--
	JP 09268189	A2	19971014	JP 1997-15135	19970129 <--
	CA 2196400	AA	19970801	CA 1997-2196400	19970130 <--
	US 5710152	A	19980120	US 1997-791269	19970130 <--
	CN 1167764	A	19971217	CN 1997-101300	19970131 <--
PRAI	JP 1996-14898	A	19960131 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 787727	ICM	C07D417-12
	ICS	A61K031-425; A61K031-505

OS MARPAT 127:205585
GI



I



II

AB The title compds. [I; R1 = alkyl, alkoxy, halo, etc.; R2, R3 = H, alkyl; R2R3 = C2-7 alkylene; R4, R5 = H, alkyl; X = O, S, NR6 (wherein R6 = H, alkyl, aryl, pyridyl); m = 0-4; n = 1-3] which exhibit superior effects for reducing blood glucose value, plasma insulin value, and plasma triglyceride value, and are useful as a medicament for preventing or treating diabetes, hyperlipidemia, and obesity, were prepared Thus, reaction of 4-[2-(4-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)ethoxy]benzaldehyde with 2,4-thiazolidinedione in the presence of a catalytic amount of AcOH and piperidine in PhMe followed by hydrogenation of the resulting thiazolidinedione II over 10% Pd/C in 1,4-dioxane afforded I [R1-R5 = H; X = O; n = 1] which showed 65.8% blood glucose reduction at 9.8 mg/kg/day.

ST benzoazine prepn blood glucose level redn; antidiabetic benzoazine prepn; hypolipemic benzoazine prepn; antiobesity agent benzoazine prepn

IT Antidiabetic agents
Antiobesity agents
Hypolipemic agents
(preparation of benzoazines for reducing blood glucose level)

IT 194713-46-7P 194713-48-9P 194713-49-0P 194713-50-3P 194713-51-4P 194713-52-5P 194713-53-6P 194713-54-7P 194713-55-8P 194713-56-9P 194713-57-0P 194713-58-1P 194713-59-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoazines for reducing blood glucose level)

IT 65-45-2, Salicylamide 77-76-9, Acetone dimethylacetal 459-57-4, p-Fluorobenzaldehyde 534-15-6, Acetaldehyde dimethylacetal 2295-31-0, 2,4-Thiazolidinedione 142558-08-5 143248-47-9 143248-50-4 143248-51-5 143248-73-1 159691-53-9 159691-57-3 159691-58-4 159691-59-5 194713-82-1 194713-83-2 194713-84-3 194713-85-4 194713-86-5 194713-87-6 194713-88-7 194713-89-8 194713-90-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzoazines for reducing blood glucose level)

IT 30914-88-6P 194713-60-5P 194713-61-6P 194713-62-7P 194713-63-8P 194713-64-9P 194713-65-0P 194713-66-1P 194713-67-2P 194713-68-3P **194713-69-4P 194713-70-7P 194713-71-8P** 194713-72-9P 194713-73-0P 194713-74-1P 194713-75-2P 194713-76-3P 194713-77-4P 194713-78-5P 194713-79-6P 194713-80-9P 194713-81-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoazines for reducing blood glucose level)

IT **194713-69-4P 194713-70-7P 194713-71-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoazines for reducing blood glucose level)

RN 194713-69-4 HCAPLUS
CN Benzaldehyde, 4-[2-(1,4-dihydro-4-oxo-1-phenyl-3(2H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 194713-70-7 HCAPLUS
CN Benzaldehyde, 4-[2-(1,4-dihydro-1-methyl-4-oxo-3(2H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 194713-71-8 HCAPLUS
CN Benzaldehyde, 4-[2-[1,4-dihydro-4-oxo-1-(2-pyridinyl)-3(2H)-quinazolinyl]ethoxy]- (9CI) (CA INDEX NAME)



L127 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:483428 HCAPLUS
DN 127:161819
ED Entered STN: 04 Aug 1997
TI Preparation and formulation of thiazolidinediones as pharmaceuticals
IN Fujita, Takeshi; Oguchi, Minoru; Wada, Kunio; Fujimoto, Koichi; Yanagisawa, Hiroaki; Fujiwara, Toshihiko; Horikoshi, Hiroyoshi; Yoshioka, Takao
PA Sankyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 171 pp.
CODEN: JKXXAF

DT Patent
LA Japanese
IC ICM C07D209-08
ICS A61K031-40; A61K031-41; A61K031-42; A61K031-425; A61K031-435; C07D209-10; C07D209-12; C07D209-36; C07D413-12; C07D417-12; C07D471-04; C07D487-04; C07D263-14; C07D271-06; C07D209-08; C07D277-34
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 09165371	A2	19970624	JP 1996-265978	19961007 <--
PRAI JP 1995-261545		19951009 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 09165371	ICM	C07D209-08
	ICS	A61K031-40; A61K031-41; A61K031-42; A61K031-425; A61K031-435; C07D209-10; C07D209-12; C07D209-36; C07D413-12; C07D417-12; C07D471-04; C07D487-04; C07D263-14; C07D271-06; C07D209-08; C07D277-34

OS MARPAT 127:161819
GI



I



II

AB The title compds. I [X = indole ring, etc.; Y = O, etc.; Z = thiazolidine-2,4-dione-5-ylmethyl, etc.; R = H, etc.; m = 1 - 5] are prepared The title compound II at 10 mg/kg orally gave 13.2% decrease in blood sugar in diabetic mice.
ST thiazolidinedione prepn pharmaceutical; antidiabetic thiazolidinedione prepn
IT Antidiabetic agents
Antihypertensives
Hypolipemic agents
(thiazolidinediones)
IT 172647-48-2P 172647-50-6P 172647-51-7P 172647-52-8P 172647-53-9P
172647-54-0P 172647-55-1P 172647-56-2P 172647-57-3P 172647-58-4P
172647-59-5P 172647-60-8P 172647-61-9P 172647-62-0P 172647-63-1P
172647-64-2P 172647-65-3P 172647-66-4P 172647-67-5P 172647-68-6P
172647-69-7P 172647-70-0P 172647-71-1P 172647-74-4P 172647-75-5P
172647-76-6P 172647-77-7P 172647-79-9P 172647-80-2P 172647-81-3P

172647-82-4P 172647-83-5P 172647-84-6P 172647-85-7P 172647-86-8P
193544-58-0P 193544-59-1P 193544-60-4P 193544-61-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolidinediones as pharmaceuticals)

IT 54-96-6, 4,5-Diaminopyridine 62-53-3, Benzenamine, reactions 62-56-6, Thiourea, reactions 74-88-4, Methyl iodide, reactions 79-14-1, Glycolic acid, reactions 96-32-2, Methyl bromoacetate 96-48-0, γ-Butyrolactone 98-80-6, Phenylboronic acid 100-02-7, reactions 100-51-6, Benzyl alcohol, reactions 104-86-9, 4-Chlorobenzylamine 120-72-9, Indole, reactions 123-08-0 271-63-6, 7-Azaindole 452-58-4, 2,3-Diaminopyridine 496-15-1, Indoline 504-29-0, 2-Aminopyridine 526-55-6, 2-(Indol-3-yl)ethanol 623-50-7, Ethyl glycolate 638-07-3, Ethyl 4-chloroacetoacetate 1072-97-5, 2-Amino-5-bromopyridine 1667-11-4, 4-(Chloromethyl)biphenyl 2295-31-0, 2,4-Thiazolidinedione 5470-18-8, 2-Chloro-3-nitropyridine 6332-56-5, 2-Hydroxy-3-nitropyridine 6602-54-6, 2-Chloro-3-cyanopyridine 16013-85-7, 2,6-Dichloro-3-nitropyridine 18162-48-6, tert-Butyldimethylsilyl chloride 18742-02-4, 2-(2-Bromoethyl)-1,3-dioxolane 24424-99-5, Di-tert-butyl-di-carbonate 24638-20-8, 1H-Imidazo[4,5-b]pyridine-2-methanol 27048-04-0 38922-77-9, Ethyl imidazo[1,2-a]pyridine-2-carboxylate 50850-16-3, 2,3-Diamino-4,6-dimethylpyridine 74772-78-4 78348-24-0, Indoline-2-carboxylic acid 92381-62-9, 1H-Imidazo[4,5-c]pyridine-2-methanol 115951-72-9 150556-72-2 172648-55-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazolidinediones as pharmaceuticals)

IT 591-81-1P 1485-22-9P 4093-88-3P 5028-20-6P 5409-39-2P 6642-26-8P, 1H-Purine-8-methanol 6945-68-2P 19786-48-2P 21755-34-0P 21755-54-4P, Imidazo[1,2-a]pyridine-2-ethanol 25710-20-7P 32329-12-7P 33140-80-6P 33742-70-0P 34949-41-2P 36404-88-3P 37493-34-8P 38875-53-5P 40851-95-4P 41010-49-5P 50501-07-0P 59954-04-0P 76182-48-4P 82090-52-6P, Imidazo[1,2-a]pyridine-2-methanol 90817-34-8P 90874-78-5P 90929-77-4P, 1H-Pyrrolo[2,3-b]pyridine-1-ethanol 91371-83-4P 94166-58-2P 121459-15-2P, 1H-Indole-1-ethanol 138969-57-0P 148433-49-2P 164224-08-2P 172647-87-9P 172647-88-0P 172647-89-1P 172647-90-4P 172647-91-5P 172647-92-6P 172647-94-8P 172647-95-9P 172647-96-0P 172647-97-1P 172647-98-2P 172648-00-9P 172648-01-0P 172648-02-1P, 1H-Imidazo[4,5-b]pyridine-2-propanol 172648-05-4P 172648-06-5P 172648-07-6P 172648-08-7P 172648-09-8P 172648-10-1P 172648-11-2P 172648-12-3P 172648-13-4P 172648-14-5P 172648-17-8P 172648-18-9P 172648-19-0P 172648-20-3P 172648-21-4P 172648-22-5P 172648-23-6P 172648-24-7P 172648-25-8P 172648-26-9P 172648-27-0P 172648-28-1P 172648-29-2P 172648-30-5P 172648-31-6P 172648-32-7P 172648-33-8P 172648-34-9P 172648-35-0P 172648-36-1P 172648-37-2P 172648-38-3P 172648-39-4P 172648-40-7P 172648-41-8P 172648-42-9P 172648-43-0P 172648-44-1P 172648-45-2P 172648-48-5P 172648-49-6P 172648-50-9P 172648-51-0P 172648-53-2P 172648-56-5P 172648-57-6P 172648-58-7P 172648-61-2P 172648-62-3P 172648-63-4P 193544-62-6P 193544-67-1P 193544-72-8P 193544-73-9P 193544-74-0P 193544-75-1P 193544-76-2P 193544-77-3P 193544-78-4P 193544-79-5P 193544-80-8P 193544-81-9P 193544-82-0P **193544-83-1P** 193546-71-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolidinediones as pharmaceuticals)

IT **193544-83-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolidinediones as pharmaceuticals)

RN 193544-83-1 HCAPLUS
CN Benzaldehyde, 4-[(3-methyl-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]- (9CI) (CA INDEX NAME)



L127 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:994680 HCAPLUS
DN 124:87002
ED Entered STN: 22 Dec 1995
TI Preparation of benzylthiazolidinediones and related compounds having antidiabetic activity.
IN Fujita, Takashi; Fujimoto, Koichi; Yoshioka, Takao; Yanagisawa, Hiroaki; Fujiwara, Toshihiko; Horikoshi, Hiroyoshi; Oguchi, Minoru; Wada, Kunio
PA Sankyo Co., Ltd., Japan
SO Eur. Pat. Appl., 166 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07D417-10
ICS C07D413-10; C07D471-04; A61K031-49; A61K031-425
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 676398	A2	19951011	EP 1995-302409	19950411 <--
	EP 676398	A3	19980701		
	EP 676398	B1	20011024		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CA 2146701	AA	19951012	CA 1995-2146701	19950410 <--
	NO 9501398	A	19951012	NO 1995-1398	19950410 <--
	RU 2114844	C1	19980710	RU 1995-105423	19950410 <--
	IL 113313	A1	19990922	IL 1995-113313	19950410 <--
	RU 2151145	C1	20000620	RU 1995-118736	19950410 <--
	CZ 289317	B6	20020116	CZ 1995-910	19950410 <--
	FI 9501731	A	19951012	FI 1995-1731	19950411 <--
	AU 9516383	A1	19951019	AU 1995-16383	19950411 <--
	AU 683348	B2	19971106		
	JP 07330728	A2	19951219	JP 1995-85161	19950411 <--
	ZA 9502990	A	19951221	ZA 1995-2990	19950411 <--
	CN 1118781	A	19960320	CN 1995-105765	19950411 <--
	CN 1060173	B	20010103		
	HU 72627	A2	19960528	HU 1995-2600	19950411 <--
	HU 73765	A2	19960930	HU 1995-1040	19950411 <--
	HU 219887	B	20010828		
	EP 1022274	A1	20000726	EP 2000-102313	19950411 <--
	EP 1022274	B1	20020828		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	TW 407156	B	20001001	TW 1995-84103469	19950411 <--
	AT 207488	E	20011115	AT 1995-302409	19950411 <--
	PT 676398	T	20020328	PT 1995-302409	19950411 <--
	ES 2165895	T3	20020401	ES 1995-302409	19950411 <--
	AT 222895	E	20020915	AT 2000-102313	19950411 <--
	TW 503237	B	20020921	TW 1998-87114283	19950411 <--
	PT 1022274	T	20021129	PT 2000-102313	19950411 <--
	ES 2180477	T3	20030216	ES 2000-102313	19950411 <--
	IL 115269	A1	19990620	IL 1995-115269	19950912 <--

	AU 9732443	A1	19971023	AU 1997-32443	19970801 <--
	AU 700354	B2	19990107		
	US 5962470	A	19991005	US 1997-1093	19971230 <--
	US 5977365	A	19991102	US 1998-110693	19980707 <--
	NO 9803900	A	19951012	NO 1998-3900	19980825 <--
	AU 9887093	A1	19981203	AU 1998-87093	19980928 <--
	AU 712294	B2	19991104		
	HK 1011365	A1	20020816	HK 1998-112512	19981130 <--
	HK 1029338	A1	20030103	HK 2000-108123	19981130 <--
	US 6117893	A	20000912	US 1999-261645	19990303 <--
PRAI	JP 1994-72083	A	19940411 <--		
	IL 1995-113313	A3	19950410 <--		
	EP 1995-302409	A3	19950411 <--		
	HU 1995-1040	A	19950411 <--		
	US 1995-419919	A3	19950411 <--		
	US 1996-713543	A3	19960913 <--		
	AU 1997-32443	A3	19970801		
	US 1997-1093	A3	19971230		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 676398	ICM	C07D417-10
	ICS	C07D413-10; C07D471-04; A61K031-49; A61K031-425

OS MARPAT 124:87002

GI





AB Title compds. [I; X = (substituted) indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl, imidazopyrimidinyl; Y = O, S; Z = Q1, Q2, CH2N(OH)CONH2, etc.; R = H, alkyl, alkoxy, halo, OH, NO2, aralkyl, (substituted) amino; m= 1-5], were prepared Thus, 5-[4-(5-chloro-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione (preparation via cyclocondensation of glycolic acid with 6-chloro-2,3-diaminopyridine given) at 1 mg/kg orally in mice showed 37.1% hypoglycemic effect.

ST benzylthiazolidinedione prepn antidiabetic; thiazolidinedione benzyl prepn antidiabetic

IT Antidiabetics and Hypoglycemics
(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)

IT 172648-35-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(benzylthiazolidinediones and related compds. having antidiabetic activity)

IT 172647-48-2P 172647-49-3P 172647-50-6P 172647-51-7P 172647-52-8P
172647-53-9P 172647-54-0P 172647-55-1P 172647-56-2P 172647-57-3P
172647-58-4P 172647-59-5P 172647-60-8P 172647-61-9P 172647-62-0P
172647-63-1P 172647-64-2P 172647-65-3P 172647-66-4P 172647-67-5P
172647-68-6P 172647-69-7P 172647-70-0P 172647-71-1P 172647-72-2P
172647-73-3P 172647-74-4P 172647-75-5P 172647-76-6P 172647-77-7P
172647-78-8P 172647-79-9P 172647-80-2P 172647-81-3P 172647-82-4P
172647-83-5P 172647-84-6P 172647-85-7P 172647-86-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)

IT 54-96-6, 4,5-Diaminopyridine 62-56-6, Thiourea, reactions 67-63-0, Isopropanol, reactions 74-88-4, Methyl iodide, reactions 74-89-5, Methanamine, reactions 75-03-6, Ethyl iodide 79-14-1, reactions 96-32-2, Methyl bromoacetate 96-48-0, γ-Butyrolactone 100-02-7, reactions 100-51-6, Benzenemethanol, reactions 104-86-9, 4-Chlorobenzylamine 108-98-5, Thiophenol, reactions 120-72-9, Indole, reactions 123-08-0, 4-Hydroxybenzaldehyde 141-32-2 271-63-6, 7-Azaindole 452-58-4, 2,3-Diaminopyridine 504-29-0, 2-Aminopyridine 623-50-7, Ethyl glycolate 637-81-0, Ethyl azidoacetate 638-07-3, Ethyl 4-chloroacetoacetate 1072-97-5, 2-Amino-5-bromopyridine 1072-98-6, 2-Amino-5-chloropyridine 1667-11-4, 4-(Chloromethyl)biphenyl 2032-35-1, Bromoacetaldehyde diethyl acetal 5470-18-8, 2-Chloro-3-nitropyridine 6332-56-5, 2-Hydroxy-3-nitropyridine 6602-54-6, 2-Chloro-3-cyanopyridine 16013-85-7, 2,6-Dichloro-3-nitropyridine 24638-20-8, 1H-Imidazo[4,5-b]pyridine-2-methanol 27048-04-0 38922-77-9, Ethyl imidazo[1,2-a]pyridine-2-carboxylate 74772-78-4 78348-24-0, Indoline-2-carboxylic acid 92381-62-9, 1H-Imidazo[4,5-c]pyridine-2-methanol 115951-72-9 150556-72-2 172648-54-3 172648-55-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)

IT 591-81-1P, 4-Hydroxybutyric acid 1485-22-9P 3723-71-5P 4093-88-3P, 2-Methylamino-3-nitropyridine 5028-20-6P 5409-39-2P 6642-26-8P, 1H-Purine-8-methanol 6945-68-2P, 2-Amino-5-bromo-3-nitropyridine 19786-48-2P 21755-34-0P 21755-54-4P, Imidazo[1,2-a]pyridine-2-ethanol 25710-20-7P, 5-Chloro-2,3-diaminopyridine 32282-18-1P 32329-12-7P 33140-80-6P 33742-70-0P 34949-41-2P 36404-88-3P, 2-Chloro-3-formylpyridine 37493-34-8P 38875-53-5P, 5-Bromo-2,3-diaminopyridine 39597-68-7P 40851-95-4P, 6-Chloro-2,3-diaminopyridine 41010-49-5P 42048-25-9P 50501-07-0P, Ethyl indoline-2-carboxylate 59954-04-0P, Methyl 4-aminophenoxyacetate 76182-48-4P 82090-52-6P, Imidazo[1,2-a]pyridine-2-methanol 90817-34-8P 90874-78-5P 90929-77-4P, 1H-Pyrrolo[2,3-b]pyridine-1-ethanol 91371-83-4P 94166-58-2P 121459-15-2P, 1H-Indole-1-ethanol 138969-57-0P 148433-49-2P 164224-08-2P 172647-87-9P 172647-88-0P 172647-89-1P 172647-90-4P 172647-91-5P 172647-92-6P 172647-93-7P 172647-94-8P 172647-95-9P 172647-96-0P 172647-97-1P 172647-98-2P 172647-99-3P 172648-00-9P 172648-01-0P 172648-02-1P, 1H-Imidazo[4,5-b]pyridine-2-propanol 172648-03-2P 172648-04-3P 172648-05-4P 172648-06-5P 172648-07-6P 172648-08-7P 172648-09-8P 172648-10-1P 172648-11-2P 172648-12-3P 172648-13-4P 172648-14-5P 172648-15-6P 172648-16-7P 172648-17-8P 172648-18-9P 172648-19-0P 172648-20-3P 172648-21-4P 172648-22-5P 172648-23-6P 172648-24-7P 172648-25-8P 172648-26-9P 172648-27-0P 172648-28-1P 172648-29-2P 172648-30-5P 172648-31-6P 172648-32-7P 172648-33-8P 172648-34-9P 172648-36-1P 172648-37-2P 172648-38-3P 172648-39-4P 172648-40-7P 172648-41-8P 172648-42-9P 172648-43-0P 172648-44-1P 172648-45-2P

172648-46-3P 172648-47-4P 172648-48-5P 172648-49-6P 172648-50-9P
172648-51-0P **172648-52-1P** 172648-53-2P 172648-56-5P
172648-57-6P 172648-58-7P 172648-59-8P 172648-60-1P 172648-61-2P
172648-62-3P 172648-63-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)

IT **172648-52-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzylthiazolidinediones and related compds. having antidiabetic activity)

RN 172648-52-1 HCAPLUS
CN Benzaldehyde, 4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)methoxy]- (9CI) (CA INDEX NAME)



=>

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 15:05:28 ON 24 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 AUG 2004  HIGHEST RN 731771-88-3
DICTIONARY FILE UPDATES:  23 AUG 2004  HIGHEST RN 731771-88-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d l53 ide can tot

L53  ANSWER 1 OF 20  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   199114-57-3  REGISTRY
CN   Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-
     quinazolinyl)ethoxy]-, ethyl ester (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C22 H23 Br N2 O4
SR   CA
LC   STN Files:   CA, CAPLUS, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  PREP (Preparation); RACT (Reactant or reagent)
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               3 REFERENCES IN FILE CA (1907 TO DATE)
               3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE   1:  135:331438

REFERENCE   2:  131:351343

REFERENCE   3:  128:13282

L53  ANSWER 2 OF 20  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   199114-56-2  REGISTRY
CN   4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI)  (CA
```

INDEX NAME)
FS 3D CONCORD
MF C17 H17 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 128:13282

L53 ANSWER 3 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-54-0** REGISTRY
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C18 H18 N2 O3 S**
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 4 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-52-8** REGISTRY
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H26 N2 O5
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



6

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 5 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-51-7** REGISTRY
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H22 N2 O5
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



5

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 6 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-48-2** REGISTRY
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H25 Br N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 7 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-47-1** REGISTRY
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H25 Br N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 8 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-46-0** REGISTRY
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H19 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 9 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-45-9** REGISTRY
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H19 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 10 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-42-6** REGISTRY
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H22 N4 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:82897

REFERENCE 2: 135:331438

REFERENCE 3: 131:351343

REFERENCE 4: 130:223293

REFERENCE 5: 128:13282

L53 ANSWER 11 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-41-5** REGISTRY
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-

methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C16 H21 N3 O3**
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:82897

REFERENCE 2: 135:331438

REFERENCE 3: 131:351343

REFERENCE 4: 130:223293

REFERENCE 5: 128:13282

L53 ANSWER 12 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-40-4** REGISTRY
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C16 H19 N3 O3**
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:82897



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 15 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-37-9** REGISTRY
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H16 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 16 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-36-8** REGISTRY

REFERENCE 2: 135:331438

REFERENCE 3: 131:351343

REFERENCE 4: 130:223293

REFERENCE 5: 128:13282

L53 ANSWER 13 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-39-1** REGISTRY
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H16 N2 O4
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 14 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-38-0** REGISTRY
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]-(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H14 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)

CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H14 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 17 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-35-7** REGISTRY
CN **Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI)** (CA INDEX NAME)
FS 3D CONCORD
MF **C17 H15 N3 O3**
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 18 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-34-6** REGISTRY
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H18 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 19 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-33-5** REGISTRY
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H16 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

L53 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2004 ACS on STN
RN **199114-32-4** REGISTRY
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H14 N2 O3
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: PREP (Preparation); RACT (Reactant or reagent)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:331438

REFERENCE 2: 131:351343

REFERENCE 3: 130:223293

REFERENCE 4: 128:13282

=> d his

(FILE 'HOME' ENTERED AT 14:07:04 ON 24 AUG 2004)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 14:07:14 ON 24 AUG 2004
L1 STR
L2 0 S L1 CSS SAM
L3 STR L1
L4 SCR 2039 OR 2127 OR 0250 OR 2049 OR 2048 OR 2053 OR 2052 OR 205
L5 SCR 1993 AND 1839
L6 SCR 1406 OR 382 OR 356
L7 0 S L3 AND L5 AND L6 NOT L4 CSS SAM

FILE 'HCAPLUS' ENTERED AT 14:21:58 ON 24 AUG 2004
L8 4 S (US6310069 OR US6114526 OR US5985884 OR US5885997)/PN OR IN96
E LOHRAY V/AU
L9 47 S E4-E10

```
                E LOHRAY B/AU
L10          121 S E4-E10
                E PARASELLI R/AU
L11           12 S E4
                E GURRAM R/AU
L12           11 S E4
                E RAMANUJAM R/AU
L13           48 S E3,E4
                E CHAKRABARTI R/AU
L14          154 S E3-E7,E15-E16
                E PAKALA S/AU
L15            3 S E5
                E REDDY/AP,CS
                E REDDY/PA,CS
L16          385 S E3-E61
                E DR REDDY/PA,CS
L17           55 S E5-E37
L18            4 S L8 AND L9-L17
                SEL RN

     FILE 'REGISTRY' ENTERED AT 14:27:49 ON 24 AUG 2004
L19          123 S E1-E123
L20           47 S L19 AND NCNC3-C6/ES
L21           41 S L20 AND 46.150.18/RID
L22           13 S L21 AND 3/NR
L23           11 S L22 NOT NITRO
L24           76 S L19 NOT L20
L25           51 S L24 AND NCNC3/ES
L26           44 S L25 AND 46.150.18/RID
L27           17 S L26 AND 2/NR
L28           16 S L27 NOT NITRO
L29            9 S L28 NOT ALDEHYDE
L30            3 S L29 AND (C12H12N2O OR C15H15N3O4)
L31            1 S L29 AND C16H21N3O3
L32            5 S L29 NOT L30,L31
L33           56 S L19 AND S/ELS
L34           53 S L33 AND 46.150.18/RID
L35            2 S L34 AND SC4-NCNC3/ES
L36            1 S L35 AND 3/NR
L37           12 S L19 AND NCNC3/ES AND 46.150.18/RID AND 2/NR NOT L32
L38            2 S L37 AND (C16H21N3O3 OR C16H19N3O3)
L39          100 S L19 AND 46.150.18/RID
L40           57 S L39 AND ETHOXY
L41           15 S L40 AND ALDEHYDE
L42            1 S C17H15N3O3 AND L41
L43           42 S L40 NOT L41
L44           14 S L43 NOT NCSC2/ES
L45           19 S L23,L32,L36,L38
L46           81 S L39 NOT L45
L47           29 S L46 NOT S/ELS
L48           24 S L47 NOT NITRO
L49           23 S L48 NOT ACETAMIDE
L50           19 S L49 NOT NCOC2/ES
L51           15 S L50 AND NR>=2
L52           11 S L51 NOT NOCNC/ES
L53           20 S L45,L42

     FILE 'HCAOLD' ENTERED AT 15:01:23 ON 24 AUG 2004
L54            0 S L53

     FILE 'HCAPLUS' ENTERED AT 15:01:26 ON 24 AUG 2004
L55            5 S L53
L56            5 S L55 AND L8-L18
```

FILE 'USPATFULL, USPAT2' ENTERED AT 15:02:09 ON 24 AUG 2004
L57 9 S L53

FILE 'REGISTRY' ENTERED AT 15:05:28 ON 24 AUG 2004

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:06:55 ON 24 AUG 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2004 VOL 141 ISS 9
FILE LAST UPDATED: 23 Aug 2004 (20040823/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l56 all hitstr tot

L56 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:418362 HCAPLUS
DN 138:82897
ED Entered STN: 04 Jun 2002
TI Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives
AU Madhavan, Gurram R.; **Chakrabarti, Ranjan**; Vikramadithyan, Reeba K.; Mamidi, Rao N. V. S.; Balraju, V.; Rajesh, B. M.; Misra, Parimal; Kumar, Sunil K. B.; **Lohray, Braj B.**; **Lohray, Vidya B.**; Rajagopalan, Ramanujam
CS **Dr. Reddy's Research Foundation, Hyderabad, 500 050, India**
SO Bioorganic & Medicinal Chemistry (2002), 10(8), 2671-2680
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Science Ltd.
DT Journal
LA English
CC 1-3 (Pharmacology)
OS CASREACT 138:82897
AB A series of pyrimidinone derivs. of thiazolidinediones were synthesized. Their biol. activity were evaluated in insulin resistant, hyperglycemic and obese db/db mice. In vitro PPARγ transactivation assay was performed in HEK 293T cells. PMT13 showed the best biol. activity in this series. PMT13 (5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy]phenylmethyl]thiazolidine-2,4-dione) showed better plasma glucose, triglyceride and insulin-lowering activity in db/db mice than rosiglitazone and pioglitazone. PMT13 showed better PPARγ transactivation than the standard compds. Pharmacokinetic study in Wistar rats showed good systemic exposure of PMT13. Twenty-eight day oral toxicity study in Wistar rats did not show any treatment-related adverse effects.
ST pyrimidinone thiazolidinedione deriv prepn structure activity antidiabetic

obesity
IT Antidiabetic agents
Hyperglycemia
Obesity
Structure-activity relationship
(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
IT Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ; synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
IT 50-99-7, D-Glucose, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(blood; synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
IT 199113-95-6P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
IT 199113-79-6P 199113-81-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
IT 199113-92-3P 199113-93-4P 199113-94-5P 199113-96-7P 199114-01-7P
199114-02-8P 199114-11-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
IT 71-30-7 141-84-4, 2-Thioxo-4-thiazolidinone 2295-31-0, Thiazolidine-2,4-dione 6622-92-0 16673-85-1 16858-16-5 16858-50-7 52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 90565-51-8 199114-65-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
IT 14631-20-0P 199113-77-4P 199113-78-5P 199113-80-9P 199114-10-8P
199114-24-4P 199114-25-5P 199114-26-6P 199114-27-7P 199114-28-8P
199114-31-3P **199114-40-4P 199114-41-5P**
199114-42-6P 199114-53-9P 199114-59-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aldo, S; J Med Chem 1995, V38, P4806
(2) Anon; Scrip 1997, V2282, P21
(3) Anon; Scrip 2001, V2668, P23
(4) Atwal, K; J Med Chem 1992, V35, P475
(5) Braj, B; J Med Chem 1998, V41, P1619

(6) Brown, D; The Pyrimidines 1994, P188
(7) DeFronzo, R; Diabetologia 1992, V35, P389 HCAPLUS
(8) Kliewer, S; Cell 1995, V83, P813 HCAPLUS
(9) Lehman, J; J Biol Chem 1995, V270, P12953
(10) Malamas, M; Eur J Med Chem 2001, V36, P31 HCAPLUS
(11) Nate, H; Chem Pharm Bull 1987, V35, P2394 HCAPLUS
(12) Patel, J; Diabetes 1997, V46(Suppl 1)
(13) Patel, J; Diabetes 1997, V46(Abstr 0578)
(14) Saltiel, A; Diabetes 1996, V45, P1661 HCAPLUS
(15) Wilson, T; J Med Chem 1996, V39, P665

IT **199114-40-4P 199114-41-5P 199114-42-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and structure-activity of novel pyrimidinone containing thiazolidinedione derivs.)

RN 199114-40-4 HCAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 HCAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 HCAPLUS
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



L56 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:792332 HCAPLUS
DN 135:331438
ED Entered STN: 31 Oct 2001
TI Preparation of heterocyclic compounds for the treatment of diabetes and related diseases
IN **Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan;**

Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.
PA **Reddy's Research Foundation, India; Reddy-Cheminor Inc.**
SO U.S., 35 pp., Cont.-in-part of U.S. 5,985,884.
CODEN: USXXAM
DT Patent
LA English
IC ICM A01K031-505
ICS C07D239-02; C07D239-70
NCL 514256000
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6310069	B1	20011030	US 2000-535387	20000324 <--
	US 5885997	A	19990323	US 1996-777627	19961231 <--
	US 5985884	A	19991116	US 1997-884816	19970630 <--
PRAI	US 1996-777627	A2	19961231		
	US 1997-884816	A2	19970630		
	IN 1996-MA1150	A	19960701 <--		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6310069	ICM	A01K031-505
	ICS	C07D239-02; C07D239-70
	NCL	514256000
US 5885997	ECLA	C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04 <--
US 5985884	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04 <--

OS MARPAT 135:331438
GI



I



II

AB The title compds. [I; one of X, Y, Z = C(O), C(S) and one of the remaining of X, Y, Z = C or C:C; R1-R3 = H, halo, OH, etc.; n = 1-4; Ar = (un)substituted divalent aryl, heteroaryl; R4 = H, halo, alkyl or forms a

bond together with the adjacent group A; A = N, CR5 (wherein R5 = H, halo, alkyl or R5 forms a bond together with R4); B = O, S when A = CR5 and B = O when A = N], novel antidiabetic compds., were prepared and formulated. Thus, reacting 4-[2-(2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl)ethoxy]benzaldehyde (preparation given) with thiazolidine-2,4-dione afforded II which showed 67% maximum reduction in blood glucose level at 100 mg/kg/day (6 days treatment) in mice.

ST heterocycle prepn antidiabetic

IT Antidiabetic agents
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 199113-77-4P 199113-78-5P 199113-79-6P 199113-80-9P 199113-83-2P
199113-85-4P 199113-86-5P 199113-88-7P 199113-89-8P 199113-93-4P
199113-95-6P 199113-98-9P 199114-00-6P 199114-02-8P 199114-10-8P
199114-12-0P 199114-15-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 199113-81-0P 199113-82-1P 199113-84-3P 199113-87-6P 199113-90-1P
199113-91-2P 199113-92-3P 199113-94-5P 199113-96-7P 199113-97-8P
199113-99-0P 199114-01-7P 199114-03-9P 199114-04-0P 199114-05-1P
199114-06-2P 199114-07-3P 199114-08-4P 199114-09-5P 199114-11-9P
199114-13-1P 199114-14-2P 199114-16-4P 199114-17-5P 199114-18-6P
199114-19-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 121-33-5, Vanillin 123-08-0, 4-Hydroxybenzaldehyde 140-88-5, Ethyl acrylate 491-36-1, 4-Oxo-3,4-dihydroquinazoline 1769-24-0 2295-31-0, Thiazolidine-2,4-dione 2346-24-9 3137-64-2 4141-08-6, 2-Amino-N-methylbenzamide 6622-92-0 13288-06-7 14631-20-0 16673-85-1 16858-16-5 16858-50-7 18593-45-8 27738-96-1, Carbonisocyanatidic chloride 28279-12-1 52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 52421-76-8 90565-51-8 199114-61-9 199114-62-0 199114-63-1 199114-64-2 199114-65-3 199114-66-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 172648-06-5P 179087-93-5P 199114-24-4P 199114-25-5P 199114-26-6P
199114-27-7P 199114-28-8P 199114-29-9P 199114-30-2P 199114-31-3P
199114-32-4P 199114-33-5P 199114-34-6P
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-43-7P 199114-44-8P
199114-45-9P 199114-46-0P 199114-47-1P
199114-48-2P 199114-49-3P 199114-50-6P **199114-51-7P**
199114-52-8P 199114-53-9P **199114-54-0P** 199114-55-1P
199114-56-2P 199114-57-3P 199114-59-5P 199114-60-8P
250256-31-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

RE.CNT 95 THERE ARE 95 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Ainsworth; US 5153210 1992 HCAPLUS
(2) Anon; JP 912575
(3) Anon; 1980 HCAPLUS

(4) Anon; EP 008203 A 1980 HCAPLUS
(5) Anon; EP 5355524 1984
(6) Anon; EP 0139421 1985 HCAPLUS
(7) Anon; EP 155845 A 1985 HCAPLUS
(8) Anon; AU 570067 1985 HCAPLUS
(9) Anon; GB 8528633 1986
(10) Anon; EP 0207581 1987 HCAPLUS
(11) Anon; EP 236624 1987 HCAPLUS
(12) Anon; JP 62175458 1987 HCAPLUS
(13) Anon; EP 0306228 1989 HCAPLUS
(14) Anon; EP 0332331 1989 HCAPLUS
(15) Anon; EP 0332332 1989 HCAPLUS
(16) Anon; EP 0337819 1989 HCAPLUS
(17) Anon; JP 6452765 1989
(18) Anon; EP 0356214 1990 HCAPLUS
(19) Anon; EP 0381371 1990
(20) Anon; EP 03974531 1990
(21) Anon; EP 0415605 1991 HCAPLUS
(22) Anon; EP 0419035 1991 HCAPLUS
(23) Anon; EP 0428312 1991 HCAPLUS
(24) Anon; EP 0439321 1991 HCAPLUS
(25) Anon; EP 0441605 1991 HCAPLUS
(26) Anon; EP 0454501 1991 HCAPLUS
(27) Anon; WO 9112003 1991 HCAPLUS
(28) Anon; WO 9207838 1992 HCAPLUS
(29) Anon; WO 9207850 1992 HCAPLUS
(30) Anon; EP 0236624 1993 HCAPLUS
(31) Anon; EP 0528734 1993 HCAPLUS
(32) Anon; EP 0543662 1993 HCAPLUS
(33) Anon; EP 0604983 1994 HCAPLUS
(34) Anon; EP 0612743 1994 HCAPLUS
(35) Anon; EP 590793 A 1994 HCAPLUS
(36) Anon; EP 605228 A 1994 HCAPLUS
(37) Anon; WO 9405659 1994 HCAPLUS
(38) Anon; WO 9425026 1994 HCAPLUS
(39) Anon; WO 9426720 1994 HCAPLUS
(40) Anon; EP 0643050 1995 HCAPLUS
(41) Anon; EP 0676398 1995 HCAPLUS
(42) Anon; EP 0678511 1995 HCAPLUS
(43) Anon; EP 645387 A 1995 HCAPLUS
(44) Anon; JP 7138258 1995
(45) Anon; WO 9507697 1995 HCAPLUS
(46) Anon; WO 9521608 1995 HCAPLUS
(47) Anon; WO 9526347 1995 HCAPLUS
(48) Anon; WO 9535108 1995 HCAPLUS
(49) Anon; EP 0708098 1996 HCAPLUS
(50) Anon; EP 0733631 1996 HCAPLUS
(51) Anon; JP 2558473 1996 HCAPLUS
(52) Anon; EP 745600 A 1996 HCAPLUS
(53) Anon; WO 9605186 1996 HCAPLUS
(54) Anon; WO 9611196 1996 HCAPLUS
(55) Anon; WO 9626207 1996 HCAPLUS
(56) Anon; WO 9741097 1996 HCAPLUS
(57) Anon; EP 0783888 1997 HCAPLUS
(58) Anon; EP 0787727 1997 HCAPLUS
(59) Anon; JP A0912575 1997
(60) Barrie, C; Journal of Medicinal Chemistry 1994, V37(23), P3977
(61) Cantello; US 5478851 1995 HCAPLUS
(62) Clark; US 5036079 1991 HCAPLUS
(63) Clark; US 5130379 1992 HCAPLUS
(64) Clark, D; J Med Chem 1991, V34, P319 HCAPLUS
(65) de Nanteuil; US 5296605 1994 HCAPLUS
(66) de Nanteuil; US 5330999 1994 HCAPLUS

(67) de Nanteuil, G; Arzneittel Forschung/Drug Design 1995, V45(II), P1176
(68) Dow; US 5498621 1996 HCAPLUS
(69) Dow, R; J Med Chem 1991, V34, P1538 HCAPLUS
(70) Goldstein; US 5037842 1991 HCAPLUS
(71) Goldstein, S; J Med Chem 1993, V36, P2238 HCAPLUS
(72) Hindley; US 5002953 1991 HCAPLUS
(73) Hindley; US 5521201 1996 HCAPLUS
(74) Hisatome; abstract of Chem Lett 1993, 8, P1357 HCAPLUS
(75) Hulin, B; J Med Chem 1992, V35(10), P1853 HCAPLUS
(76) Husain; Pharmazie 1982, V37(H6), P408
(77) Khan; Pharmazie 1988, V43(12), P864 HCAPLUS
(78) Khan, A; abstract of Pharmazie 1993, V43(12), P864 HCAPLUS
(79) Malamas; US 5420146 1995 HCAPLUS
(80) Malamas; US 5468762 1995 HCAPLUS
(81) Malamas; US 5480896 1996 HCAPLUS
(82) Meguro; US 4725610 1988 HCAPLUS
(83) Messier; Behavioral Brain Research 1996, V75, P1 HCAPLUS
(84) Nagao; US 5710152 1998 HCAPLUS
(85) Olefsky; US 5478852 1995 HCAPLUS
(86) Regnier; US 5478853 1995 HCAPLUS
(87) Rise; abstract of Acta Chem Scand 1989, V43(5), P489 HCAPLUS
(88) Schnur; US 4342771 1982 HCAPLUS
(89) Schnur; US 4367234 1983 HCAPLUS
(90) Shukla; Indian J Chem 1979, V17B, P651 HCAPLUS
(91) Sohda, T; J Med Chem 1992, V35(14), P2617 HCAPLUS
(92) Taskasi, S; Chemical Pharmaceutical Bulletin 1982, V30(10), P3580
(93) Whitcomb, R; Expert Opionion on Investigational Drugs 1995, V4(12), P1299 HCAPLUS
(94) Yano; US 5521202 1996 HCAPLUS
(95) Yoshioka; US 4873255 1989 HCAPLUS

IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

RN 199114-32-4 HCAPLUS
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 HCAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 HCAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 HCAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 HCAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 HCAPLUS
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 HCAPLUS
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 HCAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 HCAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 HCAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 HCAPLUS
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 HCAPLUS
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 HCAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-

quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 HCAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 HCAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 HCAPLUS
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 HCAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L56 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:733038 HCAPLUS
DN 131:351343
ED Entered STN: 18 Nov 1999
TI Preparation of heterocyclic compounds for the treatment of diabetes and related diseases
IN **Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.**
PA **Reddy's Research Foundation, India; Reddy-Cheminor Inc.**
SO U.S., 35 pp., Cont.-in-part of U.S. 5,885,997.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D417-12
ICS C07D239-02; C07D241-00; A61K031-505
NCL 514259000
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5985884	A	19991116	US 1997-884816	19970630 <--
	US 5885997	A	19990323	US 1996-777627	19961231 <--
	US 6114526	A	20000905	US 1999-353286	19990714 <--
	US 6310069	B1	20011030	US 2000-535387	20000324 <--
	US 6573268	B1	20030603	US 2000-535388	20000324 <--
	US 2001031759	A1	20011018	US 2001-827009	20010405 <--
	US 6372750	B2	20020416		
	US 2002123502	A1	20020905	US 2001-32846	20011226 <--
PRAI	IN 1996-MA1150	A	19960701	<--	
	US 1996-777627	A2	19961231		
	US 1997-884816	A	19970630		
	US 1999-353286	A3	19990714		
	US 2000-535388	A3	20000324		
	US 2001-827009	A3	20010405		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5985884	ICM	C07D417-12	
	ICS	C07D239-02; C07D241-00; A61K031-505	
	NCL	514259000	
US 5985884	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04	<--
US 5885997	ECLA	C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04	<--
US 6114526	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04	<--
US 6573268	ECLA	C07D239/36B; C07D495/04; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12277B; C07D471/04	<--
US 2002123502	ECLA	C07D239/36B; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/2; C07D413/12	<--

OS MARPAT 131:351343

GI



I



II

AB The title compds. [I; one of X, Y, Z = C(O), C(S) and one of the remaining of X, Y, Z = C and the other C:C; R1-R3 = H, halo, OH, etc.; n = 1-4; Ar = (un)substituted divalent aryl, heteroaryl; R4 = H, halo, alkyl or forms a bond together with the adjacent group A; A = N, CR5 (wherein R5 = H, halo, alkyl or R5 forms a bond together with R4); B = O, S when A = CR5 and B = O when A = N], novel antidiabetic compds., were prepared and formulated. Thus, reacting 4-[2-(2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl)ethoxy]benzaldehyde (preparation given) with thiazolidine-2,4-dione afforded II which showed 67% maximum reduction in blood glucose level at 100 mg/kg/day (6 days treatment) in mice.

ST heterocycle prepn antidiabetic

IT Antidiabetic agents
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 199113-77-4P 199113-78-5P 199113-79-6P 199113-80-9P 199113-83-2P
199113-85-4P 199113-86-5P 199113-88-7P 199113-89-8P 199113-93-4P
199113-95-6P 199113-98-9P 199114-00-6P 199114-02-8P 199114-10-8P
199114-12-0P 199114-15-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 199113-81-0P 199113-82-1P 199113-84-3P 199113-87-6P 199113-90-1P
199113-91-2P 199113-92-3P 199113-94-5P 199113-96-7P 199113-97-8P
199113-99-0P 199114-01-7P 199114-03-9P 199114-04-0P 199114-05-1P
199114-06-2P 199114-07-3P 199114-08-4P 199114-09-5P 199114-11-9P
199114-13-1P 199114-14-2P 199114-16-4P 199114-17-5P 199114-18-6P
199114-19-7P 199114-21-1P 199114-22-2P 199114-23-3P 250256-30-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 121-33-5, Vanillin 123-08-0, 4-Hydroxybenzaldehyde 140-88-5, Ethyl acrylate 491-36-1, 4-Oxo-3,4-dihydroquinazoline 1769-24-0 2295-31-0, Thiazolidine-2,4-dione 2346-24-9 3137-64-2 4141-08-6, 2-Amino-N-methylbenzamide 6622-92-0 13288-06-7 14631-20-0 16673-85-1 16858-16-5 16858-50-7 18593-45-8 27738-96-1, Carbonisocyanatidic chloride 28279-12-1 52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 52421-76-8 90565-51-8 199114-61-9 199114-62-0 199114-63-1 199114-64-2 199114-65-3 199114-66-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

IT 172648-06-5P 179087-93-5P 199114-24-4P 199114-25-5P 199114-26-6P
199114-27-7P 199114-28-8P 199114-29-9P 199114-30-2P 199114-31-3P
199114-32-4P 199114-33-5P 199114-34-6P
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-43-7P 199114-44-8P
199114-45-9P 199114-46-0P 199114-47-1P
199114-48-2P 199114-49-3P 199114-50-6P **199114-51-7P**
199114-52-8P 199114-53-9P **199114-54-0P** 199114-55-1P
199114-56-2P 199114-57-3P 199114-59-5P 199114-60-8P
250256-31-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

RE.CNT 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Ainsworth; US 5153210 1992 HCAPLUS
(2) Anon; JP 09-12575 A HCAPLUS
(3) Anon; AU 570067 HCAPLUS
(4) Anon; GB 8528633
(5) Anon; 1980 HCAPLUS
(6) Anon; EP 008203A 1980
(7) Anon; EP 0139421 1985 HCAPLUS
(8) Anon; EP 155845 A 1985 HCAPLUS
(9) Anon; WO 9605186 1986 HCAPLUS
(10) Anon; EP 0207581 1987 HCAPLUS
(11) Anon; EP 0306228 1989 HCAPLUS
(12) Anon; EP 0332332 1989 HCAPLUS
(13) Anon; EP 0337819 1989 HCAPLUS
(14) Anon; JP 06-452765 1989

(15) Anon; EP 0356214 1990 HCAPLUS
(16) Anon; EP 0381371 1990
(17) Anon; EP 0397453 1990 HCAPLUS
(18) Anon; EP 0415605 1991 HCAPLUS
(19) Anon; EP 0419035 1991 HCAPLUS
(20) Anon; EP 0428312 1991 HCAPLUS
(21) Anon; EP 0439321 1991 HCAPLUS
(22) Anon; EP 0441605 1991 HCAPLUS
(23) Anon; EP 0454501 1991 HCAPLUS
(24) Anon; WO 9207838 1992 HCAPLUS
(25) Anon; WO 9207850 1992 HCAPLUS
(26) Anon; EP 0236624 1993 HCAPLUS
(27) Anon; EP 0528734 1993 HCAPLUS
(28) Anon; EP 0543662 1993 HCAPLUS
(29) Anon; EP 0604983 1994 HCAPLUS
(30) Anon; EP 0612743 1994 HCAPLUS
(31) Anon; EP 590793 A 1994 HCAPLUS
(32) Anon; EP 605227 A 1994 HCAPLUS
(33) Anon; WO 9405659 1994 HCAPLUS
(34) Anon; WO 9426720 1994 HCAPLUS
(35) Anon; EP 0643050 1995 HCAPLUS
(36) Anon; EP 0676398 1995 HCAPLUS
(37) Anon; EP 0678511 1995 HCAPLUS
(38) Anon; JP 07-138258 1995 HCAPLUS
(39) Anon; EP 645387 A 1995 HCAPLUS
(40) Anon; WO 9507697 1995 HCAPLUS
(41) Anon; WO 9521608 1995 HCAPLUS
(42) Anon; WO 9526347 1995 HCAPLUS
(43) Anon; WO 9535108 1995 HCAPLUS
(44) Anon; EP 0708098 1996 HCAPLUS
(45) Anon; EP 0733631 1996 HCAPLUS
(46) Anon; EP 745600 A 1996 HCAPLUS
(47) Anon; WO 9611196 1996 HCAPLUS
(48) Anon; WO 9626207 1996 HCAPLUS
(49) Anon; EP 0783888 1997 HCAPLUS
(50) Anon; EP 0787727 1997 HCAPLUS
(51) Anon; JP 09-12575 1997 HCAPLUS
(52) Anon; Behavioral Brain Research 1996, V75, P1
(53) Anon; Chemical Pharmaceutical Bulletin 1982, V30(10), P3580
(54) Cantello; US 5478851 1995 HCAPLUS
(55) Cantello; Journal of Medicinal Chemistry 1994, V37(23), P3977 HCAPLUS
(56) Clark; US 5036079 1991 HCAPLUS
(57) Clark; US 5130379 1992 HCAPLUS
(58) Clark, D; J Med Chem 1991, V34, P319 HCAPLUS
(59) De Nanteuil; US 5296605 1994 HCAPLUS
(60) De Nanteuil; US 5330999 1994 HCAPLUS
(61) De Nanteuil, G; Arzneittel Forschung/Drug Design 1995, V45(II), P1176
(62) Dow; US 5498621 1996 HCAPLUS
(63) Dow, R; J Med Chem 1991, V34, P1538 HCAPLUS
(64) Goldstein; US 5037842 1991 HCAPLUS
(65) Goldstein, S; J Med Chem 1993, V36, P2238 HCAPLUS
(66) Hindley; US 5002953 1991 HCAPLUS
(67) Hindley; US 5521201 1996 HCAPLUS
(68) Hulin, B; J Med Chem 1992, V35(10), P1853 HCAPLUS
(69) Husain; Pharmazie 1982, V37(6), P408 HCAPLUS
(70) Khan, A; Pharmazie 1988, V43(12), P864 HCAPLUS
(71) Malamas; US 5420146 1995 HCAPLUS
(72) Malamas; US 5468762 1995 HCAPLUS
(73) Malamas; US 5480896 1996 HCAPLUS
(74) Meguro; US 4725610 1988 HCAPLUS
(75) Nagao; US 5710152 1998 HCAPLUS
(76) Olefsky; US 5478852 1995 HCAPLUS
(77) Regnier; US 5478853 1995 HCAPLUS

(78) Schnur; US 4342771 1982 HCAPLUS
(79) Schnur; US 4367234 1983 HCAPLUS
(80) Shukla, J; Indian Journal Chemical 1979, V17B(6), P651 HCAPLUS
(81) Sohda, T; J Med Chem 1992, V35(14), P2617 HCAPLUS
(82) Whitcomb, R; Expert Opinion on Investigational Drugs 1995, V4(12), P1299 HCAPLUS
(83) Yano; US 5521202 1996 HCAPLUS
(84) Yushioka; US 4873255 1989 HCAPLUS

IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)

RN 199114-32-4 HCAPLUS
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 HCAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 HCAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 HCAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 HCAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 HCAPLUS
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 HCAPLUS
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 HCAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 HCAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 HCAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 HCAPLUS
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 HCAPLUS
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 HCAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 HCAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 HCAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 HCAPLUS
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 HCAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L56 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:212642 HCAPLUS
DN 130:223293
ED Entered STN: 05 Apr 1999
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN **Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema**
PA **Reddy's Research Foundation, India; Reddy-Cheminor, Inc.**
SO U.S., 26 pp.
CODEN: USXXAM

DT Patent
LA English
IC ICM C07D417-12
ICS A61K031-425
NCL 514256000
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5885997	A	19990323	US 1996-777627	19961231	<--
	CA 2258949	AA	19971106	CA 1997-2258949	19970630	<--
	WO 9741097	A2	19971106	WO 1997-US11522	19970630	
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	AU 9737198	A1	19971119	AU 1997-37198	19970630	
	AU 744518	B2	20020228			
	US 5985884	A	19991116	US 1997-884816	19970630	<--
	EP 958296	A1	19991124	EP 1997-934041	19970630	<--
	EP 958296	B1	20030730			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI					
	BR 9711098	A	20000308	BR 1997-11098	19970630	<--
	CN 1275982	A	20001206	CN 1997-195778	19970630	
	JP 2002515874	T2	20020528	JP 1997-539307	19970630	
	IL 127296	A1	20030112	IL 1997-127296	19970630	
	RU 2200161	C2	20030310	RU 1998-123195	19970630	
	AT 246190	E	20030815	AT 1997-934041	19970630	
	PT 958296	T	20031128	PT 1997-934041	19970630	
	ES 2199366	T3	20040216	ES 1997-934041	19970630	
	ZA 9705866	A	19980223	ZA 1997-5866	19970701	<--
	MX 9810782	A	20001130	MX 1998-10782	19981215	
	NO 9806055	A	19981222	NO 1998-6055	19981222	
	US 6114526	A	20000905	US 1999-353286	19990714	<--
	US 6310069	B1	20011030	US 2000-535387	20000324	<--
	US 6573268	B1	20030603	US 2000-535388	20000324	<--
	US 2001031759	A1	20011018	US 2001-827009	20010405	<--
	US 6372750	B2	20020416			
	US 2002123502	A1	20020905	US 2001-32846	20011226	<--
PRAI	IN 1996-MA1150	A	19960701	<--		
	US 1996-777627	A	19961231			
	US 1997-884816	A	19970630			
	WO 1997-US11522	W	19970630			
	US 1999-353286	A3	19990714			
	US 2000-535388	A3	20000324			
	US 2001-827009	A3	20010405			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
US 5885997	ICM	C07D417-12	
	ICS	A61K031-425	
	NCL	514256000	
US 5885997	ECLA	C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04	
WO 9741097	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04	<--
US 5985884	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34;	

		C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04 <--
US 6114526	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04 <--
US 6573268	ECLA	C07D239/36B; C07D495/04; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12277B; C07D471/04 <--
US 2002123502	ECLA	C07D239/36B; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/2; C07D413/12 <--

OS MARPAT 130:223293

GI



I



II

AB The present invention relates to novel antidiabetic compds., their tautomeric forms, their derivs., their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compns. containing them. This invention particularly relates to novel azolidinedione derivs., and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compns. containing them. Approx. 30 title compds. such as I (R = Pr, Me, Et, Bu, benzyl) and their quinazoline analogs were prepared in 66-99% yields, e.g., by condensation of aldehydes II with thiazolidine-2,4-dione. Antidiabetic data was given for several of the prepared compds. At 30 mg/kg/day, after 6 days, 5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,5-dihydro-1-pyrimidinyl]ethoxy]phenylmethyl] thiazolidine-2,4-dione reduced the blood glucose level 73%, lowered triglycerides 70% and also lowered cholesterol in the rat.

ST antidiabetic pyrimidinylethoxybenzylthiazolidinedione prepn; thiazolidinedione pyrimidinylethoxybenzyl prepn

IT Antidiabetic agents
(preparation of pyrimidinylethoxybenzylthiazolidinediones)

IT 199113-79-6P 199113-83-2P 199113-88-7P 199113-89-8P 199113-98-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidinylethoxybenzylthiazolidinediones)

IT 199113-82-1P 199113-85-4P 199113-93-4P 199113-95-6P 199113-97-8P 199114-00-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of pyrimidinylethoxybenzylthiazolidinediones)
IT 121-33-5, Vanillin 123-08-0, 4-Hydroxybenzaldehyde 140-88-5
491-36-1, 3,4-Dihydroquinazolin-4-one 1769-24-0 2295-31-0,
Thiazolidine-2,4-dione 2346-24-9 3137-64-2 3282-30-2, Pivaloyl
chloride 4141-08-6, o-Amino-N-methylbenzamide 6622-92-0 13288-06-7
14631-20-0 16673-85-1 16858-16-5 16858-50-7 18593-45-8
28279-12-1 52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 52421-76-8
90565-51-8 179087-93-5 199114-61-9 221208-19-1 221208-20-4
221208-21-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidinylethoxybenzylthiazolidinediones)
IT 199113-77-4P 199113-78-5P 199113-80-9P 199114-02-8P 199114-24-4P
199114-25-5P 199114-26-6P 199114-27-7P 199114-28-8P 199114-29-9P
199114-30-2P 199114-31-3P **199114-32-4P 199114-33-5P**
199114-34-6P 199114-35-7P 199114-36-8P
199114-37-9P 199114-38-0P 199114-39-1P
199114-40-4P 199114-41-5P 199114-42-6P
199114-43-7P 199114-44-8P **199114-45-9P 199114-46-0P**
199114-47-1P 199114-48-2P 199114-51-7P
199114-52-8P 199114-53-9P **199114-54-0P** 221208-06-6P
221208-08-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyrimidinylethoxybenzylthiazolidinediones)
IT 199113-81-0P 199113-84-3P 199113-86-5P 199113-87-6P 199113-90-1P
199113-91-2P 199113-92-3P 199113-94-5P 199113-96-7P 199113-99-0P
199114-03-9P 199114-04-0P 199114-05-1P 221207-99-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrimidinylethoxybenzylthiazolidinediones)
RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon; EP 008203 A 1980 HCAPLUS
(2) Anon; EP 155845 A 1985 HCAPLUS
(3) Anon; EP 2139421 1985
(4) Anon; AU 570067 1985 HCAPLUS
(5) Anon; GB 8528633 1986
(6) Anon; EP 0207581 1987 HCAPLUS
(7) Anon; EP 0236624 1987 HCAPLUS
(8) Anon; EP 0306228 1989 HCAPLUS
(9) Anon; EP 0332331 1989 HCAPLUS
(10) Anon; EP 0332332 1989 HCAPLUS
(11) Anon; EP 0337819 1989 HCAPLUS
(12) Anon; EP 0397453 1990 HCAPLUS
(13) Anon; EP 0415605 1991 HCAPLUS
(14) Anon; EP 0419035 1991 HCAPLUS
(15) Anon; EP 0439321 1991 HCAPLUS
(16) Anon; EP 0441605 1991 HCAPLUS
(17) Anon; EP 0454501 1991 HCAPLUS
(18) Anon; GB 9112003 1991
(19) Anon; GB 9207838 1992
(20) Anon; GB 9207850 1992
(21) Anon; EP 0528734 1993 HCAPLUS
(22) Anon; EP 0543662 1993 HCAPLUS
(23) Anon; EP 0604983 1994 HCAPLUS
(24) Anon; EP 590793 A 1994 HCAPLUS
(25) Anon; EP 605228 A 1994 HCAPLUS
(26) Anon; GB 9405659 1994
(27) Anon; GB 9425026 1994
(28) Anon; EP 0676398 1995 HCAPLUS
(29) Anon; EP 0678511 1995 HCAPLUS
(30) Anon; EP 645387 A 1995 HCAPLUS
(31) Anon; JP 7138258 1995
(32) Anon; GB 9507697 1995

(33) Anon; GB 9521608 1995
(34) Anon; GB 9535108 1995
(35) Anon; EP 745600 A 1996 HCAPLUS
(36) Anon; EP 0783888 1997 HCAPLUS
(37) Anon; EP 0787727 1997 HCAPLUS
(38) Anon; Journal of Medicinal Chemistry 1994, V37(23)
(39) Answorth; US 5153210 1992 HCAPLUS
(40) Cantello; US 5478851 1995 HCAPLUS
(41) Clark; US 5036079 1991 HCAPLUS
(42) Clark; US 5130797 1992
(43) de Nanteuil; US 5296605 1994 HCAPLUS
(44) de Nanteuil; US 5330999 1994 HCAPLUS
(45) de Nanteuil, G; Arzneittel Forschung/Drug Design 1995, V45(II), P1176
(46) Goldstein; US 5037842 1991 HCAPLUS
(47) Goldstein; US 5334604 1994 HCAPLUS
(48) Hindley; US 5002953 1991 HCAPLUS
(49) Hindley; US 5521201 1996 HCAPLUS
(50) Malamus; US 5420146 1995 HCAPLUS
(51) Meguno; US 4725610 1988 HCAPLUS
(52) Messler; Behavioural Brain Research 1996, V75, P1
(53) Olefsky; US 5478852 1995 HCAPLUS
(54) Takashi; Chemical and Pharmaceutical Bulletin 1982, V30(10), P3580
(55) Whitcomb, R; "Thiazolidediones", Expert Opinion on Investigational Drugs 1995, V4(12), P1299 HCAPLUS
(56) Yano; US 5521202 1996 HCAPLUS
(57) Yoshioka; US 4873255 1989 HCAPLUS

IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidinylethoxybenzylthiazolidinediones)

RN 199114-32-4 HCAPLUS
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 HCAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 HCAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA

INDEX NAME)



RN 199114-35-7 HCAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 HCAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 HCAPLUS
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 HCAPLUS
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 HCAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 HCAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 HCAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 HCAPLUS
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 HCAPLUS
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 HCAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 HCAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 HCAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 HCAPLUS
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



L56 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:740205 HCAPLUS
DN 128:13282
ED Entered STN: 24 Nov 1997
TI Preparation of thiazolidinediones and analogs as antidiabetics
IN **Lohray, Vidya Bhushan; Lohray, Braj Bhushan; Paraselli, Rao Bheema; Gurram, Ranga Madhavan; Ramanujam, Rajagopalan; Chakrabarti, Ranjan; Pakala, Sarma K. S.**
PA **Dr. Reddy's Research Foundation, India; Reddy-Cheminor, Inc.**
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07D
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9741097	A2	19971106	WO 1997-US11522	19970630

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,
VN, YU, ZW
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG

US 5885997	A	19990323	US 1996-777627	19961231	<--
AU 9737198	A1	19971119	AU 1997-37198	19970630	
AU 744518	B2	20020228			
EP 958296	A1	19991124	EP 1997-934041	19970630	<--
EP 958296	B1	20030730			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI					
BR 9711098	A	20000308	BR 1997-11098	19970630	<--
JP 2002515874	T2	20020528	JP 1997-539307	19970630	
IL 127296	A1	20030112	IL 1997-127296	19970630	
RU 2200161	C2	20030310	RU 1998-123195	19970630	
AT 246190	E	20030815	AT 1997-934041	19970630	
MX 9810782	A	20001130	MX 1998-10782	19981215	
NO 9806055	A	19981222	NO 1998-6055	19981222	
PRAI US 1996-777627	A	19961231			
IN 1996-MA1150	A	19960701	<--		
WO 1997-US11522	W	19970630			

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9741097	ICM	C07D
WO 9741097	ECLA	C07D239/36B; C07D239/46C3; C07D239/88; C07D277/34; C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04
US 5885997	ECLA	C07D413/12; C07D413/12; C07D413/12; C07D417/12; C07D417/12; C07D471/04; C07D495/04 <--

OS MARPAT 128:13282

GI



I



II

AB Title compds. [I; A = N, CR5; B = O or S; R = CHR4ZO(CH2)nR1; R1 = (un)substituted pyrimidinyl, -quinazolinyl, etc.; R4,R5 = H, halo, alkyl; R4R5 = bond; Z = divalent aromatic or heterocyclic group; n = 1-4] were prepared Thus, 4-methyl-2-propyl-1,6-dihydro-6-pyrimidinone was N-alkylated by 4-(BrCH2CH2O)C6H4CHO and the product condensed with thiazolidine-2,4-dione to give, after hydrogenation, title compound II. Data for biol. activity of I were given.

ST thiazolidinedione prepn antidiabetic

IT Antidiabetic agents
Hypolipemic agents
(preparation of thiazolidinediones and analogs as antidiabetics)

IT 199113-77-4P 199113-78-5P 199113-79-6P 199113-80-9P 199113-81-0P
199113-82-1P 199113-83-2P 199113-84-3P 199113-85-4P 199113-86-5P
199113-87-6P 199113-88-7P 199113-89-8P 199113-90-1P 199113-91-2P
199113-92-3P 199113-93-4P 199113-94-5P 199113-95-6P 199113-96-7P
199113-97-8P 199113-98-9P 199113-99-0P 199114-00-6P 199114-01-7P

199114-02-8P 199114-03-9P 199114-04-0P 199114-05-1P 199114-06-2P
199114-07-3P 199114-08-4P 199114-09-5P 199114-10-8P 199114-11-9P
199114-12-0P 199114-13-1P 199114-14-2P 199114-15-3P 199114-16-4P
199114-17-5P 199114-18-6P 199114-19-7P 199114-20-0P 199114-21-1P
199114-22-2P 199114-23-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolidinediones and analogs as antidiabetics)

IT 121-33-5, Vanillin 123-08-0, 4-Hydroxybenzaldehyde 140-88-5
491-36-1, 4-Oxo-3,4-dihydroquinazoline 1769-24-0 2295-31-0,
Thiazolidine-2,4-dione 2346-24-9, 2-Thioxo-1,3-oxazolidin-4-one
3137-64-2 4141-08-6, 2-Amino-N-methylbenzamide 6622-92-0 14631-20-0
16673-85-1 16858-16-5 16858-50-7 18593-45-8 28279-12-1
52191-15-8, 4-(2-Bromoethoxy)benzaldehyde 52421-76-8 57279-70-6,
4-(2-Bromoethoxy)-1-nitrobenzene 90565-51-8 199114-61-9 199114-62-0
199114-63-1 199114-64-2 199114-65-3 199114-66-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazolidinediones and analogs as antidiabetics)

IT 172648-06-5P 179087-93-5P 199114-24-4P 199114-25-5P 199114-26-6P
199114-27-7P 199114-28-8P 199114-29-9P 199114-30-2P 199114-31-3P
199114-32-4P 199114-33-5P 199114-34-6P
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-43-7P 199114-44-8P
199114-45-9P 199114-46-0P 199114-47-1P
199114-48-2P 199114-49-3P 199114-50-6P **199114-51-7P**
199114-52-8P 199114-53-9P **199114-54-0P** 199114-55-1P
199114-56-2P 199114-57-3P 199114-58-4P 199114-59-5P
199114-60-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolidinediones and analogs as antidiabetics)

IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolidinediones and analogs as antidiabetics)

RN 199114-32-4 HCAPLUS
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 HCAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 HCAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 HCAPLUS
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 HCAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 HCAPLUS
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 HCAPLUS
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]-
(9CI) (CA INDEX NAME)



RN 199114-39-1 HCAPLUS
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-
methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 HCAPLUS
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-,
1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 HCAPLUS
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-
methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 HCAPLUS
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 HCAPLUS
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 HCAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-

quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 HCAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 HCAPLUS
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 HCAPLUS
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 HCAPLUS
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 HCAPLUS
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



=> fil uspatall
FILE 'USPATFULL' ENTERED AT 15:07:43 ON 24 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:07:43 ON 24 AUG 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr tot

L57 ANSWER 1 OF 9 USPATFULL on STN
AN 2003:148981 USPATFULL
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan, Hyderabad, INDIA
Lohray, Braj Bhushan, Hyderabad, INDIA
Paraselli, Rao Bheema, Hyderabad, INDIA
Gurram, Ranga Madhavan, Hyderabad, INDIA
Ramanujam, Rajagopalan, Hyderabad, INDIA
Chakrabarti, Ranjan, Hyderabad, INDIA
Pakala, Sarma K. S., Hyderabad, INDIA
PA Dr. Reddy's Laboratories Ltd., Hyderabad, INDIA (non-U.S. corporation)
PI US 6573268 B1 20030603
AI US 2000-535388 20000324 (9)
RLI Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, now patented, Pat. No. US 6114526 Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, now patented, Pat. No. US 5985884 Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997
PRAI IN 1996-115096 19960701
DT Utility
FS GRANTED
EXNAM Primary Examiner: Qazi, Sabiha
LREP Ladas & Parry
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2738

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
(preparation of thiazolidinediones and analogs as antidiabetics)

RN 199114-32-4 USPATFULL

CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 USPATFULL

CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 USPATFULL

CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 USPATFULL

CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 USPATFULL
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 USPATFULL
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 USPATFULL
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPATFULL
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPATFULL
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPATFULL
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 2 OF 9 USPATFULL on STN
AN 2002:228341 USPATFULL
TI Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan, Hyderabad, INDIA
Lohray, Braj Bhushan, Hyderabad, INDIA
Paraselli, Rao Bheema, Hyderabad, INDIA
Gurram, Ranga Madhavan, Hyderabad, INDIA
Ramanujam, Rajagopalan, Hyderabad, INDIA
Chakrabarti, Ranjan, Hyderabad, INDIA
Pakala, Sarma K.S., Hyderabad, INDIA

PA DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. (non-U.S. corporation)
PI US 2002123502 A1 20020905
US 6780992 B2 20040824
AI US 2001-32846 A1 20011226 (10)
RLI Division of Ser. No. US 2001-827009, filed on 5 Apr 2001, PENDING
Division of Ser. No. US 2000-535388, filed on 24 Mar 2000, PENDING
Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, PATENTED
Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, PATENTED
Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996, PATENTED
PRAI IN 1996-115096 19960701
DT Utility
FS APPLICATION
LREP LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutical compositions containing them ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
(preparation of thiazolidinediones and analogs as antidiabetics)
RN 199114-32-4 USPATFULL
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 USPATFULL
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 USPATFULL
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 USPATFULL
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPATFULL
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPATFULL
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPATFULL
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 3 OF 9 USPATFULL on STN
AN 2001:191137 USPATFULL
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan, Hyderabad, India
Lohray, Braj Bhushan, Hyderabad, India
Paraselli, Rao Bheema, Hyderabad, India
Gurram, Ranga Madhavan, Hyderabad, India
Ramanujam, Rajagopalan, Hyderabad, India
Chakrabarti, Ranjan, Hyderabad, India
Pakala, Sarma K. S., Hyderabad, India
PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)
Reddy-Cheminor Inc., Ridgewood, NJ, United States (U.S. corporation)
PI US 6310069 B1 20011030
AI US 2000-535387 20000324 (9)
RLI Continuation-in-part of Ser. No. US 1997-884816, filed on 30 Jun 1997, now patented, Pat. No. US 5985884 Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997
DT Utility
FS GRANTED
EXNAM Primary Examiner: Qaz, Sabiha N.
LREP Ladas & Parry
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2623
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)
RN 199114-32-4 USPATFULL
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 USPATFULL
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 USPATFULL
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 USPATFULL
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPATFULL
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPATFULL
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPATFULL
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 4 OF 9 USPATFULL on STN
AN 2001:182599 USPATFULL
TI Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Dya Bhushan, Hyderabad, India
Lohray, Raj Bhushan, Hyderabad, India
Paraselli, Rao Bheema, Hyderabad, India
Gurram, Ranga Madhavan, Hyderabad, India
Ramanujam, Rajagopalan, Hyderabad, India
Chakrabarti, Ranjan, Hyderabad, India
Pakala, Sarma K.S., Hyderabad, India
PA DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. (non-U.S. corporation)
PI US 2001031759 A1 20011018
US 6372750 B2 20020416
AI US 2001-827009 A1 20010405 (9)
RLI Division of Ser. No. US 2000-535388, filed on 24 Mar 2000, PENDING Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, GRANTED, Pat. No. US 6114526 Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, GRANTED, Pat. No. US 5985884 Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996, GRANTED, Pat. No. US 5885997
PRAI IN 1996-115096 19960701
DT Utility
FS APPLICATION
LREP LADAS & PARRY, 26 WEST 61ST STREET, NEW YORK, NY, 10023
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2922
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P

199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
(preparation of thiazolidinediones and analogs as antidiabetics)

RN 199114-32-4 USPATFULL
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 USPATFULL
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 USPATFULL
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 USPATFULL
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPATFULL
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPATFULL
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-

pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPATFULL
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 5 OF 9 USPATFULL on STN
AN 2000:117907 USPATFULL
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan, Hyderabad, India
Lohray, Braj Bhushan, Hyderabad, India
Paraselli, Rao Bheema, Hyderabad, India
Gurram, Ranga Madhavan, Hyderabad, India
Ramanujam, Rajagopalan, Hyderabad, India
Chakrabarti, Ranjan, Hyderabad, India
Pakala, Sarma K.S., Hyderabad, India
PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)
Reddy-Cheminor Inc., Ridgewood, NJ, United States (U.S. corporation)
PI US 6114526 20000905
AI US 1999-353286 19990714 (9)
RLI Continuation of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997 76 Ser. No. US 1997-884816, filed on 30 Jun 1997
PRAI IN 1996-115096 19960701
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Qazi, Sabiha N.
LREP Ladas & Parry
CLMN Number of Claims: 5

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
(preparation of thiazolidinediones and analogs as antidiabetics)
RN 199114-32-4 USPATFULL
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]-

(9CI) (CA INDEX NAME)



RN 199114-36-8 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-
(9CI) (CA INDEX NAME)



RN 199114-37-9 USPATFULL
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI)
(CA INDEX NAME)



RN 199114-38-0 USPATFULL
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]-
(9CI) (CA INDEX NAME)



RN 199114-39-1 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-
methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 USPATFULL
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPATFULL
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPATFULL
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPATFULL
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 6 OF 9 USPATFULL on STN
AN 1999:146583 USPATFULL
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan, Jubilee Hills, India
Lohray, Braj Bhushan, Jubilee Hills, India
Paraselli, Rao Bheema, Miyapur, India
Gurram, Ranga Madhavan, Miyapur, India
Ramanujam, Rajagopalan, Yellareddy Guda, India
Chakrabarti, Ranjan, Nagar, India
Pakala, Sarma K. S., Kukatpally, India

PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)
Reddy-Cheminor Inc., Ridgewood, NJ, United States (U.S. corporation)
PI US 5985884 19991116
AI US 1997-884816 19970630 (8)
RLI Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997
PRAI IN 1996-115096 19960701
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Qazi, Sabiha N.
LREP Ladas & Parry
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
(preparation of heterocyclic compds. for the treatment of diabetes and related diseases)
RN 199114-32-4 USPATFULL
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA

INDEX NAME)



RN 199114-35-7 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 USPATFULL
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 USPATFULL
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 USPATFULL
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPATFULL
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPATFULL
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPATFULL
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 7 OF 9 USPATFULL on STN
AN 1999:37111 USPATFULL
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan, Hyderabad, India
Lohray, Braj Bhushan, Hyderabad, India
Paraselli, Rao Bheema, Hyderabad, India
PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)
Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)
PI US 5885997 19990323
AI US 1996-777627 19961231 (8)
PRAI IN 1996-115096 19960701
DT Utility
FS Granted
EXNAM Primary Examiner: Dees, Jose G.; Assistant Examiner: Oazi, Sabiha N.
LREP Ladas & Parry
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1914
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
(preparation of pyrimidinylethoxybenzylthiazolidinediones)
RN 199114-32-4 USPATFULL
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 USPATFULL
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 USPATFULL
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 USPATFULL
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 USPATFULL
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 USPATFULL
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 USPATFULL
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPATFULL
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPATFULL
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPATFULL
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 USPATFULL
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-

quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 USPATFULL
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPATFULL
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



L57 ANSWER 8 OF 9 USPAT2 on STN
AN 2002:228341 USPAT2
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan, Hyderabad, INDIA
Lohray, Braj Bhushan, Hyderabad, INDIA
Paraselli, Rao Bheema, Hyderabad, INDIA
Gurram, Ranga Madhavan, Hyderabad, INDIA
Ramanujam, Rajagopalan, Hyderabad, INDIA

Chakrabarti, Ranjan, Hyderabad, INDIA
Pakala, Sarma K.S., Hyderabad, INDIA
PA Dr. Reddy's Laboratories Ltd., Hyderabad, INDIA (non-U.S. corporation)
Dr. Reddy's Laboratories Inc., Bridgewater, NJ, United States (U.S. corporation)
PI US 6780992 B2 20040824
AI US 2001-32846 20011226 (10)
RLI Division of Ser. No. US 2001-827009, filed on 5 Apr 2001, now patented, Pat. No. US 6372750 Division of Ser. No. US 2000-535388, filed on 24 Mar 2000 Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, now patented, Pat. No. US 6114526 Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, now patented, Pat. No. US 5985884 Continuation-in-part of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997
PRAI IN 1996-115096 19960701
DT Utility
FS GRANTED
EXNAM Primary Examiner: Qazi, Sabiha
LREP Ladas & Parry
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2537
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
(preparation of thiazolidinediones and analogs as antidiabetics)
RN 199114-32-4 USPAT2
CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 USPAT2
CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 USPAT2
CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 USPAT2
CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 USPAT2
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 USPAT2
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 USPAT2
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 USPAT2
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 USPAT2
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, 1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 USPAT2
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPAT2
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPAT2
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPAT2
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 USPAT2
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 USPAT2
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-

quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPAT2
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 USPAT2
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPAT2
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPAT2
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPAT2
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L57 ANSWER 9 OF 9 USPAT2 on STN
AN 2001:182599 USPAT2
TI Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
IN Lohray, Vidya Bhushan, Hyderabad, INDIA
Lohray, Braj Bhushan, Hyderabad, INDIA
Paraselli, Rao Bheema, Hyderabad, INDIA
Gurram, Ranga Madhavan, Hyderabad, INDIA
Ramanujam, Rajagopalan, Hyderabad, INDIA
Chakrabarti, Ranjan, Hyderabad, INDIA
Pakala, Sarma K. S., Hyderabad, INDIA
PA Dr. Reddy's Research Foundation, Hyderabad, INDIA (non-U.S. corporation)
Reddy-Cheminor, Inc., Upper Saddle River, NJ, United States (U.S. corporation)
PI US 6372750 B2 20020416
AI US 2001-827009 20010405 (9)
RLI Division of Ser. No. US 2000-535388, filed on 24 Mar 2000 Division of Ser. No. US 1999-353286, filed on 14 Jul 1999, now patented, Pat. No. US 6114526 Division of Ser. No. US 1997-884816, filed on 30 Jun 1997, now patented, Pat. No. US 5985884 Division of Ser. No. US 1996-777627, filed on 31 Dec 1996, now patented, Pat. No. US 5885997
PRAI IN 1996-115096 19960701
DT Utility
FS GRANTED
EXNAM Primary Examiner: Qazi, Sabiha
LREP Ladas & Parry
CLMN Number of Claims: 2
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 2653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their

pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **199114-32-4P 199114-33-5P 199114-34-6P**
199114-35-7P 199114-36-8P 199114-37-9P
199114-38-0P 199114-39-1P 199114-40-4P
199114-41-5P 199114-42-6P 199114-45-9P
199114-46-0P 199114-47-1P 199114-48-2P
199114-51-7P 199114-52-8P 199114-54-0P
199114-56-2P 199114-57-3P
(preparation of thiazolidinediones and analogs as antidiabetics)

RN 199114-32-4 USPAT2

CN Benzaldehyde, 4-[2-(4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-33-5 USPAT2

CN Benzaldehyde, 4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-34-6 USPAT2

CN Benzaldehyde, 4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-35-7 USPAT2

CN Benzaldehyde, 4-[2-(2-methyl-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-36-8 USPAT2
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-37-9 USPAT2
CN Benzaldehyde, 4-[(3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-38-0 USPAT2
CN Benzaldehyde, 4-[(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 199114-39-1 USPAT2
CN Benzaldehyde, 4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)methoxy]-3-methoxy- (9CI) (CA INDEX NAME)



RN 199114-40-4 USPAT2
CN Benzaldehyde, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-,

1-oxime (9CI) (CA INDEX NAME)



RN 199114-41-5 USPAT2
CN 4(3H)-Pyrimidinone, 2-ethyl-3-[2-[4-[(hydroxyamino)methyl]phenoxy]ethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-42-6 USPAT2
CN Urea, N-[[4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]phenyl]methyl]-N-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-45-9 USPAT2
CN 4(3H)-Pyrimidinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl-6-methyl- (9CI) (CA INDEX NAME)



RN 199114-46-0 USPAT2
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 199114-47-1 USPAT2
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-48-2 USPAT2
CN Benzenepropanoic acid, α-bromo-4-[2-(2-ethyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-51-7 USPAT2
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy- (9CI) (CA INDEX NAME)



RN 199114-52-8 USPAT2
CN Benzenepropanoic acid, 4-[2-(2-ethyl-4-methyl-6-oxo-1(6H)-pyrimidinyl)ethoxy]-α-hydroxy-, ethyl ester (9CI) (CA INDEX NAME)



RN 199114-54-0 USPAT2
CN Benzaldehyde, 4-[2-(2,5,6-trimethyl-4-oxothieno[2,3-d]pyrimidin-3(4H)-yl)ethoxy]- (9CI) (CA INDEX NAME)



RN 199114-56-2 USPAT2
CN 4(3H)-Quinazolinone, 3-[2-(4-aminophenoxy)ethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 199114-57-3 USPAT2
CN Benzenepropanoic acid, α-bromo-4-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



=>